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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 23, Revision 4 
(FGE.23Rev4): 
 Aliphatic, alicyclic and aromatic ethers including anisole derivatives from 
chemical groups 15, 16, 22, 26 and 301
EFSA Panel on Food Contact Materials, Enzymes,  
Flavourings and Processing Aids (CEF)
 
2, 3
European Food Safety Authority (EFSA), Parma, Italy 
  
This scientific output, published on 18 March 2013, replaces the earlier version published on 19 
February 2013.4
ABSTRACT 
 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 21 flavouring substances in the Flavouring Group Evaluation 23, Revision 4, 
using the Procedure in Commission Regulation (EC) No 1565/2000. This revision is made due to the inclusion of 
one additional flavouring substance, 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran [FL-no: 
13.170]. None of the substances were considered to have genotoxic potential. The substances were evaluated 
through a stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake 
from current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The Panel 
concluded that all 21 substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 
03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687, 13.170 and 13.200] do 
not give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI approach. 
Besides the safety assessment of these flavouring substances, the specifications for the materials of commerce 
have also been considered. Specifications including complete purity criteria and identity for the materials of 
commerce have been provided for all 21 candidate substances. 
© European Food Safety Authority, 2013. 
KEY WORDS 
Flavourings, food safety, aliphatic, alicyclic, aromatic, ethers, FGE.23. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00688, adopted on 30 January 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Catherine Leclercq, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de 
Fatima Tavares Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine 
Husøy, John Christian Larsen, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific 
opinion and the hearing experts: Vibe Beltoft, Pia Lund, Karin Nørby and EFSA staff: Kim Rygaard Nielsen for the 
support provided to this scientific opinion. 
4  Editorial changes have been made to pages 1 (requesting party), 6 and 7 (History of the Evaluation) and to tables 6, 7 and 
8 (double bonds in chemical structures). The changes do not affect the overall conclusions of the scientific opinion. 
 
Flavouring Group Evaluation 23, Revision 4 
 
EFSA Journal 2013;11(2):3092 2 
SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate 21 flavouring substances in the 
Flavouring Group Evaluation 23, Revision 4 (FGE.23Rev4), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 21 aliphatic, alicyclic and aromatic ethers 
including anisole derivatives belong to chemical groups 15, 16, 22, 26 and 30, Annex I of the 
Commission Regulation (EC) No 1565/2000. 
The present revision of FGE.23, FGE23Rev4, includes the assessment of one additional flavouring 
substance, 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran [FL-no: 13.170]. 
Seven candidate substances [FL-no: 02.247, 02.248, 03.008, 03.020, 08.127, 13.170 and 13.200] 
possess one or more chiral centres. For these seven substances, the stereoisomeric composition has 
been specified. Three candidate substances [FL-no: 03.015, 03.022 and 03.024] can exist as 
geometrical isomers and the isomeric composition has been specified. 
Two of the flavouring substances are classified into structural class I, seven are classified into 
structural class II and 12 are classified into structural class III according to the decision tree approach 
presented by Cramer et al. 
Eleven of the substances in the present group have been reported to occur naturally in a wide range of 
food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when 
the Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 21 flavouring substances in this group have intakes in 
Europe from 0.011 to 49 micrograms/capita/day, which are below the threshold of concern value for 
structural class I of 1800 micrograms/person/day, for structural class II of 540 micrograms/person/day 
and for structural class III of 90 micrograms/person/day. 
The genotoxic potential of this group of flavouring substances cannot be fully assessed. However, the 
data available do not indicate a genotoxic potential and therefore do not preclude their evaluation via 
the Procedure. 
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According to the available data on supporting substances, it is expected that all 21 candidate 
substances in this group would be metabolised to innocuous products at the reported levels of intake 
as flavouring substances.  
It was noted that no repeated dose toxicity studies have been provided for any of the candidate 
substances and only a few studies were available on supporting substances. However, these 
toxicological data were consistent with the conclusions in the present Flavouring Group Evaluation 
using the Procedure. 
It was concluded that on the basis of the default MSDI approach the 21 candidate substances would 
not give rise to safety concerns at estimated levels of intake arising from their use as flavouring 
substances.  
When the estimated intakes were based on the mTAMDI approach they were 3200 
micrograms/person/day each for the two flavouring substances belonging to structural class I and for 
five of the seven flavouring substances belonging to structural class II. The mTAMDI for the 
remaining two flavouring substances from class II are 3500 and 14000 micrograms/person/day. These 
intakes are above the threshold of concern for structural class I of 1800 micrograms/person/day and 
for structural class II of 540 micrograms/person/day. For 11 of the 12 candidate substances belonging 
to structural class III the mTAMDI range from 600 to 3900 microgram/person/day, which are above 
the threshold of concern of 90 micrograms/person/day. For one substance from structural class III the 
mTAMDI of 58 micrograms/person/day is below the threshold. This substance is also expected to be 
metabolised to innocuous products.  
Thus, for 20 flavouring substances considered in this Opinion the intakes, estimated on the basis of 
the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substances have been assigned. Therefore, for these 20 substances, more reliable exposure data are 
required. On the basis of such additional data, these flavouring substances should be reconsidered 
along the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary. 
In order to determine whether the conclusion for the 21 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications 
including purity criteria and identity for the materials of commerce have been provided for all 21 
flavouring substances. 
For all the 21 substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 
03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687, 13.170 and 
13.200] the Panel concluded that they would present no safety concern at the estimated levels of 
intake based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999), as last amended by Commission Decision 2009/163/EC (EC, 
2009). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002).  
The Flavouring Group Evaluation (FGE) is revised to include substances for which data were 
submitted after the deadline as laid down in Commission Regulation (EC) No 622/2002 (EC, 2002) 
and to take into account additional information that has been made available since the previous 
Opinion on this FGE.  
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/2012 (EC, 2012). 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISION 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
The Commission requested EFSA to carry out an evaluation of the flavouring substance 5-isopropyl-
2,6-diethyl-2-methyltetrahydro-2H-pyran [FL-no: 13.200], also according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000). 
In addition, the Commission has asked EFSA to reflect newly submitted information on specifications 
in the revisions of FGEs. 
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ASSESSMENT 
1. History of the Evaluation  
The Flavouring Group Evaluation 23, FGE.23 dealt with 14 aliphatic, alicyclic and aromatic ethers 
including anisole derivatives. 
The first Revision of FGE.23, FGE.23Rev1, included the assessment of four additional candidate 
substances [FL-no: 02.247, 02.248, 03.022 and 08.127]. No toxicity or metabolism data were 
available, except for one new substance [FL-no: 02.248], for which two in vitro genotoxicity studies 
was submitted. Additional information (EFFA, 2007b) on stereoisomeric composition on two 
substances [FL-no: 03.008 and 03.020] was made available since the first FGE was published. 
The second Revision of FGE.23, FGE.23Rev2, included the assessment of one additional candidate 
substance [FL-no: 03.024]. No toxicity and/or metabolism data were provided by Industry for this 
substance. A search in open literature for this substance did not provide any further data on toxicity or 
metabolism. Since the publication of FGE.23Rev1, information on stereoisomeric composition and an 
identity test was provided by EFFA on the four substances [FL-no: 02.247, 02.248, 03.022 and 
08.127] (EFFA, 2010; EFFA, 2011a). 
The third Revision of FGE.23, FGE.23Rev3, included the assessment of one additional candidate 
substance [FL-no: 13.200]. No new metabolism data were provided by Industry for this substance. 
However, for the supporting substance [FL-no: 13.037] in vitro genotoxicity study was provided. 
Furthermore, information from Industry on stereoisomeric composition for [FL-no: 03.022] (EFFA, 
2011a) and missing information on use levels for [FL-no: 02.248] (Flavour Industry, 2011), received 
after publication of the last revision, was included in Revision 3.  
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.23 29 November 
2006 
http://www.efsa.europa.eu/en/science/afc/afc_opinions/ej417_fge23.html 14 
FGE.23Rev1 27 September 
2007 
18 http://www.efsa.europa.eu/en/efsajournal/doc/833.pdf 
FGE.23Rev2 29 September 
2010  
http://www.efsa.europa.eu/en/efsajournal/pub/1848.htm 19 
FGE.23Rev3 28 
September 
2011 
20 http://www.efsa.europa.eu/en/efsajournal/doc/2398.pdf 
FGE.23Rev4 30 January 
2013 
http://www.efsa.europa.eu/en/efsajournal/pub/3092.htm  21 
 
The present Revision of FGE.23, FGE.23Rev4, includes the assessment of one additional candidate 
substance 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran [FL-no: 13.170]. 
No new metabolism data were provided by Industry for this substance. A search in open literature for 
[FL-no: 13.170] revealed no new toxicity data other than a skin sensitisation study. 
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2. Presentation of the Substances in Flavouring Group Evaluation 23, Revision 4 
2.1. Description 
The present Flavouring Group Evaluation 23, Revision 4 (FGE.23Rev4), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (The Procedure – shown in schematic 
form in Annex I of this FGE), deals with 21 aliphatic, alicyclic or aromatic ethers. These 21 
flavouring substances (candidate substances) belong to the chemical groups 15, 16, 22, 26 and 30, 
Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000). 
The 21 candidate substances under consideration in the present evaluation are listed in Table 6, as 
well as their chemical Register names, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council 
of Europe- (CoE-) and Flavor and Extract Manufactures Association- (FEMA-) numbers, structures 
and specifications. Four of the candidate substances are aliphatic ethers [FL-no: 03.015, 03.016, 
03.022 and 03.024], three are alicyclic ethers [FL-no: 03.008, 13.170 and 13.200], three are alicyclic 
hydrocarbons with ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-no: 02.248] also 
has an acetal moiety, two are ethers containing a benzene moiety [FL-no: 03.011 and 03.012], eight 
are phenol ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687] and 
one is a naphthol ether [FL-no: 04.075].  
The outcome of the safety evaluations are summarised in Table 7. 
The hydrolysis products of the candidate esters and the acetal are listed in Table 8. 
The 21 candidate substances are structurally related to 28 flavouring substances (supporting 
substances) evaluated at the 51st JECFA meeting (JECFA, 2000) in the group of “Aliphatic acyclic 
and alicyclic terpenoid tertiary alcohols and structurally related substances”, evaluated at the 59th 
JECFA meeting (JECFA, 2002b) in the group of “Phenethyl alcohol, aldehyde, acid and related 
acetals and esters” and evaluated at the 61st JECFA meeting (JECFA, 2004a) in the group of 
“Aliphatic and aromatic ethers”. These substances, with the respective structural formulas, FEMA, 
CoE and CAS register numbers, evaluation status by the Scientific Committee on Food (SCF), the 
JECFA and the CoE, and the European Maximised Survey-derived Daily Intake (MSDI) values, are 
listed in Table 9. 
2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. 
Their flavour may be different, they may have different chemical properties resulting in possible 
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Two flavouring substances possess one chiral centre [FL-no: 03.020 and 08.127] and five possess two 
or more chiral centres [FL-no: 02.247, 02.248, 03.008, 13.170 and 13.200]. The steroisomeric 
composition has been specified for all these substances (see Table 6). 
Due to the presence and the position of double bonds three of the substances [FL-no: 03.015, 03.022 
and 03.024] can exist as geometrical isomers. The chemical Register name and the CASrn provided 
specify the configuration of the double bond for [FL-no: 03.015 and 03.024]. For [FL-no: 03.022] 
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Industry has stated that it occurs as a mixture of E- & Z-isomers with at least 40 % of each (EFFA, 
2011a) (see Table 6). 
2.3. Natural Occurrence in Food 
Eleven candidate substances in the present group have been reported to occur in spices (ginger, 
savory, vanilla, thyme, clary sage, marjoram), dried bonito, tea, juice (grapefruit, lemon), lychee fruit, 
starfruit, heated blackberry, heated beans, cape gooseberry, mushroom, smoked oily fish, brandy, rum 
and wine (TNO, 2000; TNO, 2012). Quantitative data on the natural occurrence in foods have been 
reported for three of these substances in the present Flavouring Group Evaluation. 
Table 1:  Candidate Substances Reported to Occur in Food  (TNO, 2000) 
Table 1 Candidate Substances Reported to Occur in Food  (TNO, 2000) 
FL-no: Name: Quantitative data reported 
03.015 Ethyl geranyl ether 0.0001 mg/kg in grapefruit juice, up to 0.2 mg/kg in lychee 
04.059 Carvacryl methyl ether 800 mg/kg in ginger (oil), up to 5000 mg/kg in savory (oil), up to 14400 mg/kg in thyme (oil) 
04.084 1,2,3-Trimethoxybenzene  3.8 mg/kg in dried bonito, 20 mg/kg in tea 
 
According to TNO the remaining 10 candidate substances have not been reported in any food items: 
Table 2:  Candidate substances Not Reported to Occur in Food (TNO, 2000; TNO, 2011) 
Table 2 Candidate substances Not Reported to Occur in Food (TNO, 2000; TNO, 2011) 
FL-no: Name: 
 02.247 l-Menthoxyethanol 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol acetal 
03.008 2-Acetoxy-1,8-cineole 
03.020 alpha-Terpinyl methyl ether 
03.022 1-Methoxy-1-decene 
03.024 Digeranylether 
04.067 1-Ethoxy-2-methoxybenzene 
08.127 2-(4-Methoxyphenoxy)propionic acid 
09.687 2-Phenoxyethyl butyrate 
13.200 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran 
 
3. Specifications 
Purity criteria for the 21 substances have been provided by the Flavouring Industry (EFFA, 2003a; 
EFFA, 2004a; EFFA, 2004c; Flavour Industry, 2006; Flavour Industry, 2009; Flavour Industry, 2010) 
(Table 6). 
Judged against the requirements in Annex II of Commission Regulation EC No 1565/2000 (EC, 
2000), the information is adequate for all 21 candidate substances (see Section 2.2 and Table 6). 
4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
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figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were 
conducted in 1995 by the International Organization of the Flavour Industry, in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population5
In the present Flavouring Group Evaluation 23, Revision 4 (FGE.23Rev4) the total annual volume of 
production of the 21 candidate substances for use as flavouring substances in Europe has been 
reported to be approximately 780 kg (EFFA, 2003b; EFFA, 2004a; EFFA, 2004d; EFFA, 2011b; 
Flavour Industry, 2006; Flavour Industry, 2009; Flavour Industry, 2010) and for 28 supporting 
substances approximately 34000 kg (JECFA, 2000; JECFA, 2002b; JECFA, 2004a). 
 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
                                                     
5 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU. 
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On the basis of the annual volumes of production reported for the 21 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 7). Approximately 97 % 
of the total annual volume of production for the candidate substances is accounted for by eight 
flavourings: 1-methoxyethanol [FL-no: 02.247], benzyl methyl ether [FL-no: 03.011], alpha-terpinyl 
methyl ether [FL-no: 03.020], 1-methoxy-1-decene [FL-no: 03.022], digeranyl ether [FL-no: 03.024], 
carvacryl methyl ether [FL-no: 04.059], 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-
pyran [FL-no: 13.170] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran [FL-no: 13.200]. The 
estimated daily per capita intakes of these candidate substances from use as a flavouring substance 
range from 1.2 to 49 microgram. For each of the remaining 13 substances the estimated daily per 
capita intakes are less than 0.7 microgram (Table 7). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages 
per day. 
For the present evaluation of the 21 candidate substances, information on food categories and normal 
and maximum use levels6,7,8
The 21 candidate substances are used in flavoured food products divided into the food categories, 
outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000), as shown in 
Table 3. For the present calculation of mTAMDI, the reported normal use levels were used. In the 
case where different use levels were reported for different food categories the highest reported normal 
use level was used. 
 were submitted, by the Flavour Industry (EFFA, 2003a; EFFA, 2004a; 
EFFA, 2004c; EFFA, 2007a; EFFA, 2012; Flavour Industry, 2006; Flavour Industry, 2008; Flavour 
Industry, 2009; Flavour Industry, 2010; Flavour Industry, 2011). 
                                                     
6 “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002). 
7 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004b). 
8 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 “Alcoholic 
beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007). 
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Table 3:  Use of Candidate Substances in Various Food Categories 
Table 3 Use of Candidate Substances in Various Food Categories 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All except [FL-no: 
02.248, 03.024] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 
03.024, 13.170] 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 
02.248, 13.170] 
04.1 Processed fruits All except [FL-no: 
02.248, 03.024, 
13.170] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no: 02.248, 
03.022, 13.200] 
05.0 Confectionery All  
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
All except [FL-no: 
03.022, 03.024, 
13.170] 
07.0 Bakery wares All except [FL-no: 
03.024] 
08.0 Meat and meat products, including poultry and game All except [FL-no: 
02.248, 03.024, 
13.170, 13.200] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 
03.024, 13.170, 
13.200] 
10.0 Eggs and egg products Only [FL-no: 13.200] 
11.0 Sweeteners, including honey Only [FL-no: 13.200] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 
03.024] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 
02.248, 03.022, 
03.024, 13.170, 
13.200] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All except [FL-no: 
13.170] 
15.0 Ready-to-eat savouries All except [FL-no: 
02.248, 03.008, 
03.024, 13.170, 
13.200] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All except [FL-no: 
13.170, 13.200] 
 
According to the Flavour Industry the normal use levels for the 21 candidate substances are in the 
range of 0.0015 to 70 mg/kg food and the maximum use levels are in the range of 0.0125 to 100 
mg/kg (EFFA, 2003a; EFFA, 2004a; EFFA, 2004c; EFFA, 2007a; EFFA, 2012; Flavour Industry, 
2006; Flavour Industry, 2008; Flavour Industry, 2009; Flavour Industry, 2010; Flavour Industry, 
2011) (see Table II.1.2, Appendix II). The mTAMDI values for the 21 candidate substances from 
structural class I, II and III (see Section 6) are in the range of 58 to 14000 micrograms/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Annex II. 
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5. Absorption, Distribution, Metabolism and Elimination 
The candidate substances are examples of aliphatic, alicyclic or aromatic ethers. On the basis of their 
structure they can be divided into seven subgroups:  
1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022],  
2) alicyclic ethers [FL-no: 03.008, 13.170 and 13.200],  
3) alicyclic hydrocarbons with an ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-
no: 02.248] also has an acetal moiety,  
4) benzyl ethers [FL-no: 03.011 and 03.012], 
5) phenol ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687],  
6) naphthol ethers [FL-no: 04.075] and  
7) long chain aliphatic ethers [FL-no: 03.024] (see Table 4). 
No data on absorption, distribution, metabolism or elimination are reported for the 21 candidate 
substances.  
According to the available data on supporting substances, all the candidate are expected to be rapidly 
absorbed from the gastrointestinal tract and excreted in the exhaled air as CO2 and as polar 
metabolites in the urine.  
After absorption, the supporting substance, beta-naphthyl methyl ether [FL-no: 04.033], 
representative for the naphthol ether in subgroup 6 [FL-no: 04.075], is hydroxylated and excreted as a 
glucuronide. 
Concerning their biotransformation, it can be expected that the straight-chain aliphatic ethers included 
in subgroup 1 may undergo O-dealkylation in vivo, catalysed by cytochrome P450, to yield the 
corresponding alcohol and aldehyde that subsequently undergo complete oxidation in the fatty acid 
pathway and tricarboxylic acid cycle. The demethylated product of 1-methoxy-1-decene [FL-no: 
03.022] is an enol, which will rearrange to the aldehyde, which subsequently can be oxidised to the 
carboxylic acid. 
The candidate substances, 2-acetoxy-1,8-cineole [FL-no: 03.008], 2S-cis-tetrahydro-4-methyl-2-(2-
methyl-1-propenyl)-2H-pyran [FL-no: 13.170] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-
pyran [FL-no: 13.200], within subgroup 2 (alicyclic ether), on the basis of information on the 
representative supporting substance [FL-no: 03.008], may be anticipated to undergo ring-
hydroxylation by P450, conjugation with glucuronic acid followed by excretion in the urine. 
The available data on alpha-terpineol [FL-no: 02.014] and terpenoid tertiary alcohols, taken as 
supporting substances, suggest that the substance in subgroup 3 [FL-no: 03.020] would be 
metabolised by P450 isoenzymes to yield polar hydroxylated metabolites, which are conjugated to 
form glucuronic acid conjugates and excreted or are further oxidised and excreted. Cleavage of the 
ether is a minor metabolic pathway (JECFA, 1999). The acetal moiety in vanillin 3-(l-
menthoxy)propane-1,2-diol acetal [FL-no: 02.248] is shown to be hydrolysed, resulting in the 
formation of the corresponding ether and vanillin. It is expected that the alcohol group in this ether 
subsequently are oxidised and that the carboxylic acid(s) are excreted as a conjugate or excreted as 
the acid itself. Similarly, l-menthoxy ethanol [FL-no: 02.247] is anticipated to be oxidised to the 
corresponding carboxylic acid and excreted. 
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The benzyl ethers found in subgroup 4 [FL-no: 03.011 and 03.012] are expected to be metabolised in 
a similar way to mono-alkyl derivatives of benzene. It is generally accepted that mono-alkyl 
derivatives of benzene are metabolised by undergoing biotransformation of the side chain to produce 
alcohols and carboxylic acids which are eliminated in the urine as conjugates of glucuronic acid or 
glycine (Williams, 1959). 
The candidate aromatic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 
08.127 and 09.687] are expected to be metabolised by ring-hydroxylation (mainly in the para 
position, cleavage of the methyl ether (O-demethylation) and/or oxidation of the ring substituents 
depending on the position of substituents. These products would then be expected to be conjugated 
primarily with glucuronic acid and to a lesser extent sulphate or glycine and excreted in the urine. 2-
(4-Methoxyphenoxy)propionic acid [FL-no: 08.127] is expected to be excreted after conjugation or 
alternatively excreted as the unconjugated acid. 
Table 4:  Candidate Substances Divided into Subgroups of Related Chemical Structures 
Table 4 Candidate Substances Divided into Subgroups of Related Chemical Structures 
FL-no EU Register name Structural formula  
1 Aliphatic Ethers 
03.015 Ethyl geranyl ether 
O  
 
03.016 Hexyl methyl ether O   
03.022 1-Methoxy-1-decene   O
 
 
2 Alicyclic Ethers 
03.008 2-Acetoxy-1,8-cineole 
O
O
O
 
 
13.170 2S-cis-Tetrahydro-4-methyl-2-(2-methyl-1-
propenyl)-2H-pyran 
O
 
 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
O
 
 
3 Alicyclic Hydrocarbons with Ether Side Chain 
02.247 l-Menthoxyethanol 
O
OH
 
 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
O
O
O
OHO  
 
03.020 alpha-Terpinyl methyl ether  
O
 
 
4 Benzyl Ethers 
03.011 Benzyl methyl ether O
 
 
03.012 Benzyl octyl ether O
 
 
5 Phenol Ethers 
04.059 Carvacryl methyl ether 
O
 
 
04.067 1-Ethoxy-2-methoxybenzene O
O  
 
04.068 1-Ethoxy-4-methoxybenzene 
O
O
 
 
04.069 1-Ethyl-4-methoxybenzene 
O  
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04.079 Methyl 4-methoxybenzyl ether O
O  
 
04.084 1,2,3-Trimethoxybenzene 
O O
O
 
 
08.127 2-(4-Methoxyphenoxy)propionic acid O
O
OH
O  
 
09.687 2-Phenoxyethyl butyrate 
O
O
O
 
 
6 Naphthol Ethers 
04.075 1-Methoxynaphthalene 
O  
 
7 Long Chain Aliphatic Ether 
03.024 Digeranyl ether 
O
 
 
 
Metabolism data are available on the supporting substance 2-methoxynaphtalene [FL-no: 04.074] 
from subgroup 6, which is shown to be excreted as a glucuronide (Williams, 1959). 
No data are available on the absorption, distribution and excretion of the substance in subgroup 7 or 
any supporting substances but as with the other substances in this FGE, digeranyl ether would be 
expected to be rapidly absorbed from the gastrointestinal tract and excreted as polar metabolites in the 
urine and in the exhaled air as CO2. 
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether 
[FL-no: 03.024], data are available on substances that are supporting for the metabolism of longer 
chain ethers. Dealkylation of ethers becomes less likely as the chain length increases and ω-oxidation 
is more likely to occur (Tsuji et al., 1978). For geraniol, next to other pathways of metabolism related 
to the presence of a free hydroxyl-group, ω-oxidation has also been described and this would result in 
metabolism to innocuous products. As digeranyl ether contains no free hydroxyl group like geraniol, 
the other pathways for metabolism of geraniol are not available for digeranyl ether and therefore ω-
oxidation is more likely to occur. It would be expected that following ω-oxidation, the metabolites 
would be conjugated with glucuronide and excreted in the urine. 
It can be anticipated that all 21 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 
03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 
08.127, 09.687, 13.170 and 13.200] are metabolised to innocuous products. Although saturation of 
some metabolic pathways has been described, it occurs at high doses, unlikely to be reached by the 
candidate substances when used as flavouring substances at the present level of intake. 
A more detailed discussion of the metabolism of the candidate substances in this evaluation is 
provided in Annex III. 
6. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 7. 
For the safety evaluation of the 21 candidate substances from chemical groups 15, 16, 22, 26 and 30 
the Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise 
evaluations are summarised in Table 7. 
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Using the decision tree approach presented by Cramer et al., two of the candidate substances [FL-no: 
04.059 and 04.084] were classified into structural class I, seven [FL-no: 03.008, 03.011, 03.012, 
03.015, 03.016, 03.024 and 04.079] into structural class II and 12 substances [FL-no: 02.247, 02.248, 
03.020, 03.022, 04.067, 04.068, 04.069, 04.075, 08.127, 09.687, 13.170 and 13.200] into structural 
class III (Cramer et al., 1978). 
Step 1 
On the basis of the metabolism information available all 21 candidate substances [FL-no: 02.247, 
02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 
04.069, 04.075, 04.079, 04.084, 08.127, 09.687, 13.170 and 13.200] can be predicted to be 
metabolised to innocuous products and therefore they will proceed along the A-side of the Procedure 
scheme. 
Step 2 
Two candidate substances [FL-no: 04.059 and 04.084] have been assigned to structural class I and 
have estimated European daily per capita intakes (MSDI) of 1.2 and 0.012 micrograms. The seven 
candidate substances [FL-no: 03.008, 03.011, 03.012, 03.015, 03.016, 03.024 and 04.079], which 
have been assigned to structural class II have estimated European daily per capita intake ranging from 
0.012 to 49 micrograms and the 12 candidate substances [FL-no: 02.247, 02.248, 03.020, 03.022, 
04.067, 04.068, 04.069, 04.075, 08.127, 09.687, 13.170 and 13.200], which have been assigned to 
structural class III, have estimated European daily per capita intake ranging from 0.011 to 15 
micrograms (Table 5). These intakes are below the thresholds of concern of 1800, 540 and 90 
micrograms/person/day for structural class I, II and III, respectively. 
Step A3 
Based on results of the safety evaluation sequence of the Procedure, these 21 candidate substances, 
proceeding via the A-side of the Procedure scheme, do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
7. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the 21 candidate substances in structural class I, II and III based on the 
mTAMDI range from 58 to 14000 micrograms/person/day. For 20 of these substances the mTAMDI 
is above the threshold of concern of 1800 micrograms/person/day for structural class I, of 540 
micrograms/person/day for structural class II and of 90 micrograms/person/day for structural class III. 
The estimated intake for [FL-no: 03.022] in structural class III based on the mTAMDI is 58 
micrograms/person/day, which is below the threshold of concern. This substance is also expected to 
be metabolised to innocuous products. 
For 20 candidate substances the mTAMDI is above the threshold of concern for their respective 
structural class. Thus, for 20 substances further information is required. This would include more 
reliable intake data and then, if required, additional toxicological data. 
For comparison of the MSDI and mTAMDI values, see Table 5. 
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Table 5:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
Table 5 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
04.059 Carvacryl methyl ether 1.2 3200 Class I 1800 
04.084 1,2,3-Trimethoxybenzene 0.012 3200 Class I 1800 
03.008 2-Acetoxy-1,8-cineole 0.037 3500 Class II 540 
03.011 Benzyl methyl ether 1.9 3200 Class II 540 
03.012 Benzyl octyl ether 0.24 3200 Class II 540 
03.015 Ethyl geranyl ether 0.012 3200 Class II 540 
03.016 Hexyl methyl ether 0.012 3200 Class II 540 
03.024 Digeranyl ether 49 14000 Class II 540 
04.079 Methyl-4-methoxybenzyl ether 0.61 3200 Class II 540 
02.247 l-Menthoxyethanol 15 3900 Class III 90 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol acetal 0.61 2500 Class III 90 
03.020 alpha-Terpinyl methyl ether 4.1 3200 Class III 90 
03.022 1-Methoxy-1-decene 6.1 58 Class III 90 
04.067 1-Ethoxy-2-methoxybenzene 0.12 3200 Class III 90 
04.068 1-Ethoxy-4-methoxybenzene 0.67 3200 Class III 90 
04.069 1-Ethyl-4-methoxybenzene 0.073 3200 Class III 90 
04.075 1-Methoxynaphthalene 0.061 3200 Class III 90 
08.127 2-(4-Methoxyphenoxy)propionic acid 0.011 3200 Class III 90 
09.687 2-Phenoxyethyl butyrate 0.085 3900 Class III 90 
13.170 2S-cis-Tetrahydro-4-methyl-2-(2-methyl-1-
propenyl)-2H-pyran 
2.7 600 Class III 90 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
12 860 Class III 90 
 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the 
combined intake estimates are only based on MSDI exposure estimates, although it is recognised that 
this may lead to underestimation of exposure. After completion of all FGEs, this issue should be 
readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated 
by summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003b; EFFA, 2004a; 
EFFA, 2004d; EFFA, 2011b; Flavour Industry, 2006; Flavour Industry, 2009; Flavour Industry, 
2010), the combined estimated daily per capita intakes as flavourings of the two candidate substances 
assigned to structural class I, of the seven candidate substances belonging to structural class II and of 
the 12 candidate substances belonging to structural class III are 1.2, 52 and 42 micrograms, 
respectively. These values do not exceed the threshold of concern for substances belonging to 
structural class I of 1800 micrograms/person/day, structural class II of 540 microgram/person/day and 
structural class III of 90 micrograms/person/day. 
The 21 candidate substances are structurally related to 28 supporting substances evaluated by the 
JEFCA at its 51st, 59th and 61st meeting (JECFA, 1999a; JECFA, 2000; JECFA, 2002b; JECFA, 
2003a; JECFA, 2004a; JECFA, 2004b). Based on reported production volumes, European per capita 
intakes (MSDI) could be estimated for the 28 supporting substances.  
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The total combined intake of the two candidate substances and 11 supporting substances from 
structural class I is approximately 2800 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class I of 1800 micrograms/capita/day. However, the 
major contribution to the total combined intake of flavouring substances assigned to structural class I 
(99 %) is provided by the two supporting substances, namely alpha-terpineol [FL-no: 02.014] (2600 
micrograms/capita/day) and terpineol acetate [FL-no: 09.830] (220 micrograms/capita/day). 
Terpineol acetate is anticipated to be hydrolysed to alpha-terpineol. These supporting substances were 
evaluated at the 51st JECFA meeting, where it was noted that although the combined intake exceeds 
the threshold for structural class I the substances are expected to be efficiently metabolised and would 
not saturate the metabolic pathways. The Panel agreed with this view and concluded that the 
combined intake of about 1.2 micrograms/capita/day for the candidate substances in structural class I 
is negligible compared to the combined intake of 2800 micrograms/capita/day of the supporting 
substances. 
The total combined intake of the seven candidate substances and 10 supporting substances from 
structural class II is approximately 1300 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class II of 540 micrograms/person/day. More than 95 
% of the combined daily per capita intake of the supporting substances of 1250 micrograms is 
provided by the supporting substance 1,8-cineole [FL-no: 03.001]. The supporting substances in 
structural class II were evaluated at the 61st JECFA meeting, where it was noted that although the 
combined intake exceeds the threshold, the substances are expected to be efficiently metabolised and 
would not saturate the metabolic pathways. The Panel agreed with this view and concluded that the 
combined intake of about 52 micrograms/capita/day for the candidate substances in structural class II 
is negligible compared to the combined intake of 1250 micrograms/capita/day of the supporting 
substances. 
The total combined intake of the 12 candidate substances and seven supporting substances from 
structural class III for which production volumes in Europe were reported, is approximately 140 
micrograms/capita/day, which exceed the threshold of concern for a substance belonging to structural 
class III of 90 micrograms/capita/day. 
These supporting substances were evaluated by the JECFA at the 59th and 61st meetings, where it was 
noted that although the combined intake exceeds the threshold for the structural class, the substances 
are expected to be efficiently metabolised and would not saturate the metabolic pathways. The Panel 
agreed with this view and concluded that the combined intake of about 42 micrograms/capita/day for 
the candidate substances in structural class III is minor compared to the combined intake of about 100 
micrograms/capita/day of the supporting substances. 
Therefore, it can be concluded that the total combined intakes of the 21 candidate substances and 28 
supporting substances, including 1,8-cineole [FL-no: 03.001], alpha-terpineol [Fl-no: 02.014] and 
terpineol acetate [FL-no: 09.830], do not pose a safety concern. 
9. Toxicity 
9.1. Acute Toxicity 
Data are available for one of the candidate substances, ethyl-geranyl ether [FL-no: 03.015] with an 
oral LD50 value of more than 5000 mg/kg body weight (bw).  
Twenty of the 28 supporting substances were tested for acute toxicity in mice and/or rats. The oral 
LD50 values in mice and rats for the supporting substances range from 1000 mg/kg to 8000 mg/kg bw.  
Acute toxicity data are summarised in Table 10. 
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9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data on subacute and subchronic toxicity are not available for any of the candidate substances but for 
10 of the 28 supporting substances of the present flavouring group.  
Repeated dose toxicity data are summarised in Table 11. 
9.3. Developmental / Reproductive Toxicity Studies 
Data on developmental toxicity and reproductive toxicity data are not available for any of the 
candidate substances but for two of the 28 supporting substances of the present flavouring group, 1,8-
cineole [FL-no: 03.001] and phenoxyacetic acid [FL-no: 08.049].  
The data available on developmental / reproductive toxicity do not preclude the evaluation of the 
candidate substances through the Procedure. 
Developmental/reproductive toxicity data are summarised in Table 12. 
9.4. Genotoxicity Studies 
There are five genotoxicity studies carried out on the candidate substances, 1,2,3-trimethoxybenzene 
[FL-no: 04.084], vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] and 2,6-diethyl-5-
isopropyl-2-methyltetrahydro-2H-pyran [FL-no: 13.200]. One reverse mutation assay on [FL-no: 
13.200] was considered valid and gave negative results both with and without metabolic activation 
(Thompson, 2008). The four remaining studies provided negative results but are of limited value. 
There have been a number of studies carried out on the supporting substances and these generally 
show that there is no cause for concern regarding their genotoxicity. Two in vitro studies produced 
positive results; these studies are described in greater detail below. None of the in vivo tests showed 
positive results. 
One of the in vitro genotoxicity studies (Heck et al., 1989) gave a positive result for the supporting 
substance 1-methoxy-4-methylbenzene [FL-no: 04.015] at a concentration of 188 microgram/ml. This 
study was an unscheduled DNA synthesis study. The test was carried out twice, but significant 
differences were seen between the initial results and the repeat assay and there was no explanation 
why these two results may have been different. Therefore, no definite conclusions could be drawn. 
A positive result was seen in a sister chromatid exchange study on the supporting substance 1,8-
cineole [FL-no: 03.001] (Galloway et al., 1987). This study was only positive without S9 activation 
and at levels of 1,8-cineole of 200 and 500 microgram/ml, which induced cell cycle delay and 
therefore were cytotoxic. There are several other genotoxicity tests on this substance, including 
another sister chromatid exchange study (although the concentrations of test substance were much 
lower in this study), that have given negative results. In the light of these results in several 
genotoxicity studies at gene and chromosomal level the positive result in the sister chromatid 
exchange assay by Galloway (Galloway et al., 1987) is considered not to be of relevance for the 
overall evaluation. It is therefore concluded that 1,8-cineole is not genotoxic. 
In summary the Panel concluded that the genotoxicity data available do not preclude the evaluation of 
the candidate substances through the Procedure. 
Genotoxicity data are summarised in Table 13 and Table 14. 
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9.5. Other studies  
Geranium oil containing the candidate substance 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-
2H-pyran [FL-no: 13.170] at 2.2 % was found to be an extremely weak skin sensitiser in the local 
lymph node assay and a weak skin sensitiser according to the human maximisation test (Lalko and 
Api, 2006). 
The Panel concluded that this study was not adequate to form any conclusions on the dermal 
sensitisation properties of 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran [FL-no: 
13.170] due to the low concentration of the test substance, the presence of other substances in the test 
material and the weak effect observed, in accordance with previous elaborated statement of the Panel 
(EFSA, 2012). 
CONCLUSIONS 
The present revision of FGE.23, FGE23Rev4, includes the assessment of one additional flavouring 
substance, 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran [FL-no: 13.170]. 
So, FGE.23Rev4 deals in total with 21 aliphatic, alicyclic and aromatic ethers including anisole 
derivatives. 
Seven candidate substances [FL-no: 02.247, 02.248, 03.008, 03.020, 08.127, 13.170 and 13.200], 
possess one or more chiral centres. For these seven substances, the stereoisomeric composition has 
been specified. Three candidate substances [FL-no: 03.015, 03.022 and 03.024] can exist as 
geometrical isomers and the isomeric composition has been specified. 
Two of the flavouring substances are classified into structural class I, seven are classified into 
structural class II and 12 are classified into structural class III according to the decision tree approach 
presented by Cramer et al. 
Eleven of the substances in the present group have been reported to occur naturally in a wide range of 
food items. 
According to the default MSDI approach, the 21 flavouring substances in this group have intakes in 
Europe from 0.011 to 49 micrograms/capita/day, which are below the threshold of concern value for 
structural class I of 1800 micrograms/person/day, for structural class II of 540 micrograms/person/day 
and for structural class III of 90 micrograms/person/day. 
On the basis of the reported annual production in Europe (MSDI approach), the combined intake of 
the two candidate substances belonging to structural class I, of the seven candidate substances 
belonging to structural class II and of the 12 candidate substances belonging to structural class III, 
would result in combined intakes of approximately 1.2, 52 and 42 micrograms/capita/day, 
respectively. These values are lower than the thresholds of concern for structural class I, II or III 
substances. The estimated total combined intakes of the candidate and supporting substances (in 
Europe) are approximately 2800, 1300 and 140 micrograms/capita/day for structural class I, II and III 
substances, respectively.  
The combined daily per capita intake of 2800 microgram exceeds the threshold of concern of 1800 
microgram/person/day for structural class I substances. The supporting substances were evaluated at 
the 51st JECFA meeting, where it was noted that although the combined intake exceeds the threshold 
for structural class I the substances are expected to be efficiently metabolised and would not saturate 
the metabolic pathways. The Panel agreed with this view and concluded that the combined intake of 
about 1.2 micrograms/capita/day for the candidate substances in structural class I is negligible 
compared to the combined intake of 2800 micrograms/capita/day of the supporting substances. 
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Likewise, the total combined intake of the seven candidate substances and 10 supporting substances 
from structural class II is approximately 1300 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class II of 540 micrograms/person/day. The 
supporting substances in structural class II were evaluated at the 61st JECFA meeting, where it was 
noted that although the combined intake exceeds the threshold, the substances are expected to be 
efficiently metabolised and would not saturate the metabolic pathways. The Panel agreed with this 
view and concluded that the combined intake of about 52 micrograms/capita/day for the candidate 
substances in structural class II is negligible compared to the combined intake of 1250 
micrograms/capita/day of the supporting substances.  
The total combined intake of candidate and supporting substances of structural class III is 140 
micrograms/capita/day, which is above the threshold of concern for structural class III of 90 
micrograms/capita/day. The supporting substances were evaluated by the JECFA at the 59th and 61st 
meetings, where it was noted that although the combined intake exceeds the threshold for the 
structural class, the substances are expected to be efficiently metabolised and would not saturate the 
metabolic pathways. The Panel agreed with this view and concluded that the combined intake of 
about 42 micrograms/capita/day for the candidate substances in structural class III is minor compared 
to the combined intake of 100 micrograms/capita/day of the supporting substances. 
The genotoxic potential of this group of flavouring substances cannot be fully assessed as it is now. 
However, the data available do not indicate a genotoxic potential and therefore do not preclude their 
evaluation via the Procedure. 
According to the available data on supporting substances, it is expected that all 21 candidate 
substances in this group [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 
03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687, 13.170 and 
13.200] would be metabolised to innocuous products at the reported levels of intake as flavouring 
substances.  
It was noted that no repeated dose toxicity studies have been provided for any of the candidate 
substances and only a few studies were available on supporting substances. However, these 
toxicological data were consistent with the conclusions in the present Flavouring Group Evaluation 
using the Procedure. 
It was concluded that on the basis of the default MSDI approach the 21 candidate substances would 
not give rise to safety concerns at estimated levels of intake arising from their use as flavouring 
substances.  
When the estimated intakes were based on the mTAMDI approach they were 3200 
micrograms/person/day for the two flavouring substances belonging to structural class I and for five 
of the seven flavouring substances belonging to structural class II. The mTAMDI for the two 
remaining flavouring substances from class II are 3500 and 14000 micrograms/person/day. These 
intakes are above the threshold of concern for structural class I of 1800 micrograms/person/day and 
for structural class II of 540 micrograms/person/day. For 11 candidate substances belonging to 
structural class III the mTAMDI range from 600 to 3900 microgram/person/day, which are above the 
threshold of concern of 90 micrograms/person/day. For one substance from structural class III the 
mTAMDI of 58 micrograms/person/day is below the threshold. This substance is also expected to be 
metabolised to innocuous products.  
Thus, for 20 flavouring substances considered in this opinion the intakes, estimated on the basis of the 
mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring substances 
have been assigned. Thus for these 20 substances, more reliable exposure data are required. On the 
basis of such additional data, these flavouring substances should be reconsidered along the steps of 
the Procedure. Following this procedure additional toxicological data might become necessary. 
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In order to determine whether the conclusion for the 21 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications 
including purity criteria and identity for the materials of commerce have been provided for all 21 
flavouring substances. 
For all the 21 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 
03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687, 
13.170 and 13.200] the Panel concluded that they would present no safety concern at the estimated 
levels of intake based on the MSDI approach. 
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Table 6:  Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 4 
Table 6: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
4) 
Spec.gravity 
5) 
Specification comments 
02.247 
 
l-Menthoxyethanol 
O
OH
 
4154 
 
38618-23-4 
Liquid 
C12H24O2 
200.32 
Practically insoluble or 
insoluble 
Freely soluble 
100 
 
IR NMR MS 
99 % 
1.457-1.467 
0.930-0.950 
 
Register name to be changed 
to 2-(l-Menthoxy)ethanol 
(EFFA, 2010) 
02.248 
 
Vanillin 3-(l-menthoxy)propane-
1,2-diol acetal 
O
O
O
OHO  
3904 
 
180964-47-0 
Solid 
C21H32O5 
364.49 
Very slightly soluble 
Freely Soluble 
 
78-80 
IR NMR 
97 % 
n.a. 
n.a. 
 
Mixture of four 
stereoisomers with equal 
ratios of the isomers (EFFA, 
2010). 
03.008 
 
2-Acetoxy-1,8-cineole 
O
O
O
 
 
 
57709-95-2 
Solid 
C12H20O3 
212.29 
Practically insoluble or 
insoluble 
Freely soluble 
299 
89 
MS 
95 % 
n.a. 
n.a. 
 
Register name to be changed 
to (1R, 4S, 6S)-2-
Oxabicyclo[2.2.2]octan-6-ol, 
1,3,3-trimethyl-, 6-acetate 
(EFFA, 2007b). 
03.011 
 
Benzyl methyl ether O
 
 
10910 
538-86-3 
Liquid 
C8H10O 
122.17 
Practically insoluble or 
insoluble 
Freely soluble 
169 
 
MS 
95 % 
1.498-1.504 
0.962-0.968 
 
 
03.012 
 
Benzyl octyl ether O
 
 
 
54852-64-1 
Liquid 
C15H24O 
220.35 
Practically insoluble or 
insoluble 
Freely soluble 
148 (12 hPa) 
 
MS 
95 % 
1.485-1.491 
0.903-0.909 
 
 
03.015 
 
Ethyl geranyl ether 
O  
 
 
40267-72-9 
Liquid 
C12H22O 
182.31 
Practically insoluble or 
insoluble 
Freely soluble 
218 
 
MS 
95 % 
1.463-1.469 
0.861-0.867 
 
 
03.016 
 
Hexyl methyl ether O  4291 
 
4747-07-3 
Liquid 
C7H16O 
116.20 
Practically insoluble or 
insoluble 
Freely soluble 
126 
 
MS 
95 % 
1.395-1.401 
0.766-0.772 
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Table 6: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
4) 
Spec.gravity 
5) 
Specification comments 
03.020 
 
alpha-Terpinyl methyl ether 
O
 
 
 
14576-08-0 
Liquid 
C11H20O 
168.28 
Practically insoluble or 
insoluble 
Freely soluble 
216 
 
MS 
95 % 
1.461-1.467 
0.885-0.891 
 
Racemate. 
03.022 
 
1-Methoxy-1-decene O
 
4161 
 
79930-37-3 
Liquid 
C11H22O 
170 
Insoluble 
Soluble 
89 (12 hPa) 
 
IR NMR 
98 % 
1.430-1.438 
0.807-0.817 
 
Mixture of (E)- and (Z)-
isomers (EFFA, 2010).  
> 40 % E isomer and > 40 % 
Z isomer (EFFA, 2011a).  
03.024 
 
Digeranyl ether 
O
 
4664 
 
31147-36-1 
Liquid 
C20H34O 
290.48 
Sparingly soluble 
Soluble 
130 (0.33 Torr) 
 
NMR MS 
>96% 
1.477-1.487 
0.867-0.876 
 
 
04.059 
 
Carvacryl methyl ether 
O
 
 
11224 
6379-73-3 
Liquid 
C11H16O 
164.25 
Very slightly soluble 
Freely soluble 
217 
 
MS 
95 % 
1.501-1.507 
0.937-0.943 
 
 
04.067 
 
1-Ethoxy-2-methoxybenzene O
O  
 
 
17600-72-5 
Liquid 
C9H12O2 
152.19 
Very slightly soluble 
Freely soluble 
213 
 
MS 
95 % 
1.518-1.524 
1.044-1.050 
 
 
04.068 
 
1-Ethoxy-4-methoxybenzene 
O
O
 
 
 
5076-72-2 
Solid 
C9H12O2 
152.19 
Practically insoluble or 
insoluble 
Freely soluble 
217 
37 
MS 
95 % 
n.a. 
n.a. 
 
 
04.069 
 
1-Ethyl-4-methoxybenzene O
 
 
 
1515-95-3 
Liquid 
C9H12O 
136.19 
Practically insoluble or 
insoluble 
Freely soluble 
195 
 
MS 
95 % 
1.504-1.510 
0.955-0.961 
 
 
04.075 
 
1-Methoxynaphthalene 
O
 
 
 
2216-69-5 
Liquid 
C11H10O 
158.20 
Practically insoluble or 
insoluble 
Freely soluble 
270 
6 
MS 
95 % 
1.622-1.628 
1.093-1.099 
 
 
04.079 
 
Methyl-4-methoxybenzyl ether O
O
 
 
 
1515-81-7 
Liquid 
C9H12O2 
152.19 
Practically insoluble or 
insoluble 
Freely soluble 
225 
 
MS 
95 % 
1.508-1.514 
1.023-1.029 
 
Register name to be changed 
to Methyl 4-methoxybenzyl 
ether. 
04.084 
 
1,2,3-Trimethoxybenzene 
O O
O
 
 
 
634-36-6 
Solid 
C9H12O3 
168.19 
Practically insoluble or 
insoluble 
Freely soluble 
235 
47 
MS 
95 % 
n.a. 
n.a. 
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Table 6: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
4) 
Spec.gravity 
5) 
Specification comments 
08.127 
 
2-(4-Methoxyphenoxy)propionic 
acid 
O
O
OH
O
 
 
 
 
Solid 
C10H12O4 
196.20 
Slightly soluble 
Freely soluble 
377 
158 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2010). 
CASrn to be introduced in 
Register 158833-38-6. 
09.687 
 
2-Phenoxyethyl butyrate 
O
O
O
 
 
 
23511-70-8 
Liquid 
C12H16O3 
208.26 
Practically insoluble or 
insoluble 
Freely soluble 
130 (5 hPa) 
 
MS 
95 % 
1.495-1.501 
1.057-1.063 
 
 
13.170 
 
2S-cis-Tetrahydro-4-methyl-2-(2-
methyl-1-propenyl)-2H-pyran 
O
 
 
 
3033-23-6 
Liquid 
C10H18O 
154.25 
Soluble 
Soluble 
182 
 
MS 
99 % 
1.453-1.457 
0.873-0.877 
 
 
13.200 
 
5-Isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran 
O
 
4680 
 
1120363-98-5 
Liquid 
C13H26O 
198.35 
Insoluble 
Slightly soluble 
93 (10hPa) 
 
IR NMR MS 
95 % 
1.445-1.447 
0.862-0.864 
 
Approx. 61% of (2R,5R,6R)-
2,6-Diethyl-5-isopropyl-2-
methyltetrahydropyran 
(DIMP) and (2S,5S,6S)-
DIMP;  
33% of (2S,5R,6R)-DIMP 
and (2R,5S,6S)-DIMP; 4% 
of (2R,5R6S)-DIMP and 
(2S,5S,6R)-DIMP; 1% of 
(2S,5R,6S)-DIMP and 
(2R,5S,6R)-DIMP. 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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Table 7:  Summary of Safety Evaluation Applying the Procedure (Based on Intakes Calculated by the MSDI Approach) 
Table 7: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
04.059 
 
Carvacryl methyl ether 
O
 
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.084 
 
1,2,3-Trimethoxybenzene 
O O
O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
03.008 
 
2-Acetoxy-1,8-cineole 
O
O
O
 
0.037 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.011 
 
Benzyl methyl ether O
 
1.9 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.012 
 
Benzyl octyl ether O
 
0.24 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.015 
 
Ethyl geranyl ether 
O  
0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.016 
 
Hexyl methyl ether O  0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.024 
 
Digeranyl ether 
O
 
49 
 
Class II 
A3: Intake below threshold 
4) 6)  
04.079 
 
Methyl-4-methoxybenzyl ether O
O
 
0.61 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.247 
 
l-Menthoxyethanol 
O
OH
 
15 
 
Class III 
A3: Intake below threshold 
4) 6)  
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02.248 
 
Vanillin 3-(l-menthoxy)propane-
1,2-diol acetal 
O
O
O
OHO  
0.61 
 
Class III 
A3: Intake below threshold 
4) 6)  
03.020 
 
alpha-Terpinyl methyl ether 
O
 
4.1 
 
Class III 
A3: Intake below threshold 
4) 6)  
03.022 
 
1-Methoxy-1-decene O
 
6.1 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.067 
 
1-Ethoxy-2-methoxybenzene O
O  
0.12 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.068 
 
1-Ethoxy-4-methoxybenzene 
O
O
 
0.67 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.069 
 
1-Ethyl-4-methoxybenzene O
 
0.073 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.075 
 
1-Methoxynaphthalene 
O
 
0.061 
 
Class III 
A3: Intake below threshold 
4) 6)  
08.127 
 
2-(4-Methoxyphenoxy)propionic 
acid 
O
O
OH
O
 
0.011 
 
Class III 
A3: Intake below threshold 
4) 6)  
09.687 
 
2-Phenoxyethyl butyrate 
O
O
O
 
0.085 
 
Class III 
A3: Intake below threshold 
4) 6)  
13.170 
 
2S-cis-Tetrahydro-4-methyl-2-(2-
methyl-1-propenyl)-2H-pyran 
O
 
2.7 
 
Class III 
A3: Intake below threshold 
4) 6)  
13.200 
 
5-Isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran 
O
 
12 
 
Class III 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
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5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 6 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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Table 8:  Evaluation Status of Hydrolysis Products of Candidate Esters and Acetals 
Table 8: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 2-Hydroxy-1.8-cineole 
O
OH
 
Not evaluated as flavouring substance  Not in EU-Register 
 2-Phenoxyethanol 
O
OH
 
Not evaluated as flavouring substance  Not in EU-Register 
02.224 3-(1-Menthoxy)propane-
1,2-diol 
1408 
O OH
OH
 
 
No safety concern a) 
 
 
Class I 
A3: Intake below threshold 
 
05.018 Vanillin 
889 
HO
O
O
 
 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold,  
A4: Not endogenous,  
A5: Adequate NOAEL exists 
 
08.002 Acetic acid 
81 O
OH  
Category 1 d) 
No safety concern e) 
Category A c) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 d) 
No safety concern e) 
Category A c) 
 
Class I 
A3: Intake above threshold,  
A4: Endogenous 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2005). 
b) (JECFA, 2002a). 
c) (CoE, 1992). 
d) (SCF, 1995). 
e) (JECFA, 1999b). 
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Table 9:   Supporting Substances Summary 
Table 9: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.014 alpha-Terpineol 
HO
 
3045 
62 
98-55-5 
366 
JECFA specification (JECFA, 
1998) 
2600  
No safety concern a) 
Category A b) 
 
03.001 1,8-Cineole 
O
 
2465 
182 
470-82-6 
1234 
JECFA specification (JECFA, 
2003b). 
1200  
No safety concern c) 
Category B b) 
 
03.003 Benzyl ethyl ether O
 
2144 
521 
539-30-0 
1252 
JECFA specification (JECFA, 
2003b). 
0.0024  
No safety concern c) 
Deleted b) 
 
03.005 2-Butyl ethyl ether O
 
3131 
10911 
2679-87-0 
1231 
JECFA specification (JECFA, 
2003b). 
6.9  
No safety concern c) 
 
 
03.006 2-Methoxyethyl benzene O
 
3198 
11812 
3558-60-9 
1254 
JECFA specification (JECFA, 
2003b). 
26  
No safety concern c) 
 
 
03.007 1,4-Cineole 
O
 
3658 
11225 
470-67-7 
1233 
JECFA specification (JECFA, 
2003b). 
3.9  
No safety concern c) 
 
 
03.010 Benzyl butyl ether O
 
2139 
520 
588-67-0 
1253 
JECFA specification (JECFA, 
2003b). 
0.012  
No safety concern c) 
Deleted b) 
 
03.019 Prenyl ethyl ether O
 
3777 
 
22094-00-4 
1232 
JECFA specification (JECFA, 
2003b). 
21  
No safety concern c) 
 
 
04.014 1-Methoxy-2-methylbenzene O
 
2680 
187 
578-58-5 
1242 
JECFA specification (JECFA, 
2003b). 
2.4  
No safety concern c) 
Deleted b) 
 
04.015 1-Methoxy-4-methylbenzene O
 
2681 
188 
104-93-8 
1243 
JECFA specification (JECFA, 
2003b). 
0.49  
No safety concern c) 
Category B b) 
 
04.016 1,3-Dimethoxybenzene OO
 
2385 
189 
151-10-0 
1249 
JECFA specification (JECFA, 
2003b). 
4.6  
No safety concern c) 
Category A b) 
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Table 9: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
04.032 Anisole O
 
2097 
2056 
100-66-3 
1241 
JECFA specification (JECFA, 
2003b). 
0.024  
No safety concern c) 
Category B b) 
 
04.033 beta-Naphthyl ethyl ether O
 
2768 
2058 
93-18-5 
1258 
JECFA specification (JECFA, 
2003b). 
43  
No safety concern c) 
Category A b) 
 
04.034 1,4-Dimethoxybenzene O
O  
2386 
2059 
150-78-7 
1250 
JECFA specification (JECFA, 
2003b). 
15  
No safety concern c) 
Category A b) 
 
04.038 Carvacryl ethyl ether 
O
 
2246 
11840 
4732-13-2 
1247 
JECFA specification (JECFA, 
2003b). 
0.085  
No safety concern c) 
 
 
04.039 1-Methoxy-4-propylbenzene O
 
2930 
11835 
104-45-0 
1244 
JECFA specification (JECFA, 
2003b). 
20  
No safety concern c) 
 
No ADI allocated 
(JECFA, 1981). 
04.040 1,2-Dimethoxy-4-vinylbenzene O
O  
3138 
11228 
6380-23-0 
1251 
JECFA specification (JECFA, 
2003b). 
0.012  
No safety concern c) 
 
 
04.043 1-Isopropyl-2-methoxy-4-
methylbenzene 
O
 
3436 
11245 
1076-56-8 
1246 
JECFA specification (JECFA, 
2003b). 
1.7  
No safety concern c) 
 
 
04.054 Isobutyl beta-naphthyl ether 
O
 
3719 
11886 
2173-57-1 
1259 
JECFA specification (JECFA, 
2003b). 
1.2  
No safety concern c) 
 
 
04.062 1,2-Dimethoxybenzene O
O  
3799 
10320 
91-16-7 
1248 
JECFA specification (JECFA, 
2003b). 
1.6  
No safety concern c) 
 
 
04.063 1,3-Dimethyl-4-
methoxybenzene O
 
3828 
 
6738-23-4 
1245 
JECFA specification (JECFA, 
2003b). 
0.12  
No safety concern c) 
 
 
04.074 2-Methoxynaphthalene O
 
 
 
93-04-9 
1257 
JECFA specification (JECFA, 
2003b). 
3.5  
No safety concern c) 
 
 
08.049 Phenoxyacetic acid 
O
OH
O
 
2872 
2005 
122-59-8 
1026 
JECFA specification (JECFA, 
2002c). 
30  
No safety concern d) 
Deleted b) 
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Table 9: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(µg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.487 2-Phenoxyethyl isobutyrate 
O
O
O  
2873 
2089 
103-60-6 
1028 
JECFA specification (JECFA, 
2002c). 
1.7  
No safety concern d) 
Deleted b) 
 
09.830 Terpineol acetate 
O
O
 
3047 
205 
8007-35-0 
368 
JECFA specification (JECFA, 
1998) 
220  
No safety concern a) 
 
 
13.037 2-(2-Methylprop-1-enyl)-4-
methyltetrahydropyran 
O
 
3236 
2269 
16409-43-1 
1237 
JECFA specification (JECFA, 
2003b). 
3.8  
No safety concern c) 
Category B b) 
 
13.088 3,6-Dihydro-4-methyl-2-(2-
methylprop-1-en-1-yl)-2H-
pyran 
O
 
3661 
 
1786-08-9 
1235 
JECFA specification (JECFA, 
2003b). 
0.85  
No safety concern c) 
 
 
13.094 2,6,6-Trimethyl-2-
vinyltetrahydropyran 
O
 
3735 
10976 
7392-19-0 
1236 
JECFA specification (JECFA, 
2003b). 
0.024  
No safety concern c) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2000). 
b) (CoE, 1992). 
c) (JECFA, 2004a). 
d) (JECFA, 2002b). 
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TOXICITY TABLES 
Table 10:  Acute Toxicity 
Oral acute toxicity data are available for one candidate substance of the present Flavouring Group Evaluation and for 20 supporting substances evaluated by 
the JECFA at the 51st, 59th and 61st meeting (JECFA, 1999a; JECFA, 2003a; JECFA, 2004b). The supporting substances are listed in brackets. 
TABLE 10: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Anisole [04.032]) Rat M, F Oral 3700 (Taylor et al., 1964)  
 Rat M, F Oral 3700 (Bär and Griepentrog, 1967)  
 Rat M, F Oral 3700 (Jenner et al., 1964)  
(1-Methoxy-4-methylbenzene [04.015]) Rat M, F Oral 1920 (Wong and Hart, 1971)  
(1,3-Dimethyl-4-methoxybenzene [04.063]) Rat M, F Oral > 2000 (Gilman, 1997)  
(1,3-Dimethoxybenzene 04.016]) Rat NR Oral 2500 (Moreno, 1978a)  
 Rat M, F Oral 2560 (Bär and Griepentrog, 1967)  
(1,4-Dimethoxybenzene [04.034]) Rat NR Oral 3600 (Moreno, 1973a)  
(Prenyl ethyl ether [03.019]) Mouse M Oral 24 hours:  
1000 – 8000 ;  
14 days:  
1000 – 4000 
(Bähler and Bonetti, 1983)  
Ethyl geranyl ether [03.015] Rat NR Oral > 5000 (Moreno, 1977a)  
(1,4-Cineole [03.007]) Rat NR Oral 3100 (Moreno, 1981)  
(1,8-Cineole [03.001]) Rat M, F Oral 2480 (Bär and Griepentrog, 1967)  
 Rat M, F Oral 2480 (Jenner et al., 1964)  
 Rat M, F Oral 1550 (Brownlee, 1940)  
(3,6-Dihydro-4-methyl-2-(2-methylprop-1-en-1-yl)-2H-pyran 
[13.088]) 
Rat NR Oral ~ 5000 (Moreno, 1980)  
(2,2,6-Trimethyl-6-vinyltetrahydropyran [13.094]) Rat M, F Oral 2700 (Sauer-Freeman, 1980)  
 Mouse NR Oral 4000 – 8000 (Roure Bertrand Dupont, 1979)  
(2-(2-Methylprop-1-enyl)-4-methyltetrahydropyran [13.037]) Rat NR Oral 4300 (Opdyke, 1976)  
(2-Methoxyethyl benzene [03.006]) Rat NR Oral 4100 (Moreno, 1977b)  
(1-Methoxy-4-propylbenzene [04.039]) Rat M, F Oral 4400 (Taylor et al., 1964)  
 Rat M, F Oral 4400 (Jenner et al., 1964)  
 Rat M, F Oral 4400 (Bär and Griepentrog, 1967)  
 Mouse NR Oral 7300 (Jenner et al., 1964)  
(2- Methoxynaphthalene [04.074]) Rat NR Oral > 5000 (Levenstein, 1974)  
 Mouse M, F Oral 825 (Schafer and Bowles, 1985)  
(beta-Naphthyl ethyl ether [04.033]) Rat M, F Oral 3110 (Wong and Weir, 1971)  
 Mouse M, F Oral 1213 (Schafer and Bowles, 1985)  
(Isobutyl beta-naphthyl ether [04.054]) Rat M, F Oral 5930 (Jenner et al., 1964)  
 Rat NR Oral > 5000 (Moreno, 1978b)  
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TABLE 10: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
 Rat M, F Oral 5930 (Bär and Griepentrog, 1967)  
(2-Phenoxyethyl isobutyrate [09.487]) Rat NR Oral > 5000 (Moreno, 1973b)  
(Phenoxyacetic acid [08.049]) Rat M, F Gavage 1800 (Burdock and Ford, 1990)  
 Rat M, F Gavage 1772 (Piccirillo, 1983)  
 Rat NR Oral > 5000 (Moreno, 1976)  
(alpha-Terpineol [02.014]) Rat NR Oral 43001 (Moreno, 1971)  
 Mouse M Gavage 2830 (Yamahara et al., 1985)  
(Terpineol acetate [09.830]) Rat M, F Gavage 5075 (Jenner et al., 1964)  
M = Male; F = Female.  
NR = Not reported.  
1 Reported for a mixture of alpha- and beta-terpineol. 
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Table 11:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Subacute / subchronic / chronic / carcinogenicity toxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation 
but for 10 supporting substances evaluated by the JECFA at the 51st, 61st meeting (JECFA, 1999a; JECFA, 2004b). The supporting substances are listed in 
brackets. 
TABLE 11: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(1-Methoxy-4-methylbenzene 
[04.015]) 
Rat; M, F 
20 
Gavage 40, 120, 240 
mg/kg bw/day 
28 days 40 (Brunsborg et al., 1994) 1. 
 Rat; M, F 
10 
Gavage 100, 300, 1000 
mg/kg bw/day 
28 days 
(4 weeks) 
100 (BASF, 1995)  
(Carvacryl ethyl ether [04.038]) Rat; M, F 
10 
Diet 22 mg/kg bw/day 14 days M: < 22  
F : 22 
(Gill and Van Miller, 1987) 1. 
(1,2-Dimethoxybenzene [04.062]) Rat; M, F 
10 
Diet 10 mg/kg bw/day 14 days 10 (Trimmer et al., 1992) 1. 
(1,3-Dimethoxybenzene [04.016]) Rat; M, F 
30 
Diet M: 9.6 mg/kg 
bw/day 
F: 11.2 mg/kg 
bw/day 
90 days M: 9.6  
F: 11.2 
(Oser et al., 1965) 1. 
 Rat; M, F Diet  84 days 
(12 weeks) 
10 (Bär and Griepentrog, 1967) 1. 
 Rat; M, F 
20 or 40 
Diet 0.1 and 0.5 % 
equivalent to 50, 
250 mg/kg bw/day 
730 days 
(2 years) 
250  (Bär and Griepentrog, 1967) 1. 
(1,4-Dimethoxybenzene [04.034]) Rat; M, F 
5 or 10 
Diet 2 % in diet 
equivalent to 1000 
mg/kg bw/day 
28 or 56 days 1000 (Altmann et al., 1985) 1. 
(1,8-Cineole [03.001]) Rat; M, F 
12 
Gavage 150, 300, 600, 
1200 mg/kg 
bw/day 
28 days M: 300  
F: 1200 
(NTP, 1987a) 1. 
 Rat; M, F 
12 
Diet 3750, 7500, 
15000, 30000 
ppm equal to 381, 
766, 1740, 3342 
mg/kg bw/day for 
males and 353, 
765, 1527, 3516 
mg/kg bw/day for 
females 
28 days M: Not established  
F: 1500 
(NTP, 1987a) 1. 
 Mouse; M, F 
12 
Gavage 150, 300, 600, 
1200 mg/kg 
bw/day 
28 days 1200 (NTP, 1987b) 1. 
Liver/body weight ratio: 1. vehicle effect 
males 20 % increase, females 8 % 
decrease. 2. inconclusive dose-response 
relationship. 
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TABLE 11: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
 Mouse; M, F 
12 
Diet 3750, 7500, 
15000, 30000 
ppm equal to 600, 
1322, 2448, 5607 
mg/kg bw/day for 
males and 705, 
1532, 3152, 6777 
mg/kg bw/day for 
females  
28 days M: 562.5 
F: 1125 
(NTP, 1987b) 1. 
 Mouse; M 
52 
Gavage 8, 32 mg/kg 
bw/day 
560 days 32 (Roe et al., 1979) 1. 
The mice were dosed with a mixture of 
substances which also included 
chloroform and peppermint oil. This 
study is of limited value as only a small 
number of organs were studied for 
histopathological changes. 
(2-(2-Methylprop-1-enyl)-4-
methyltetrahydropyran [13.037]) 
Rat; M, F 
20 - 32 
Diet M: 2.514 mg/kg 
bw/day 
F: 2.805 mg/kg 
bw/day 
90 days M: 2.514 
F: 2.805 
(Posternak et al., 1969) 1. 
(1-Methoxy-4-propylbenzene 
[04.039]) 
Rat; M 
20 
Gavage Initial dose 2000, 
gradually increase 
to 5000 mg/kg 
bw/day 
32 days Not established (Hagan et al., 1967) 1. 
 Rat; M, F 
20 
Diet  133 days 
(19 weeks) 
Not established (Hagan et al., 1967) 1. 
(beta-Naphthyl ethyl ether [04.033]) Rat; M, F 
30 
Diet M: 5.1 mg/kg 
bw/day 
F: 5.7 mg/kg 
bw/day 
90 days M: 5.1 
F: 5.7 
(Oser et al., 1965) 1. 
 Rat; NR Diet  84 days 
(12 weeks) 
5.0 (Bär and Griepentrog, 1967) 1. 
(Terpineol acetate [09.830]) Rat; M, F 
20 
Diet 0, 1000, 2500 or 
10,000 ppm, 
equivalent to 0, 
50, 125 or 500 
mg/kg bw/day 
140 days 
(20 weeks) 
500 (Hagan et al., 1967) 2. 
Very limited details provided. 
 
M = Male; F = Female.  
NR = Not reported.  
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 51st  meeting (JECFA,1999a). 
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Table 12:  Developmental and Reproductive Toxicity Studies 
Developmental and reproductive toxicity data are available for none of candidate substances of the present Flavouring Group Evaluation but for two 
supporting substances evaluated by the JECFA at the 59th and 61st meeting (JECFA, 2003a; JECFA, 2004b). Supporting substance listed in brackets. 
TABLE 12: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no] Species/ Sex 
No./ group 
Route Dose 
Levels 
Duration NOAEL (mg/kg 
bw/day), Including 
information of 
possible maternel 
toxicity 
Reference Comments 
(1,8-Cineole [03.001]) Rat / F 
12 – 17 
Gavage 0.16, 0.8, 1.6 ml/kg 
 
Developmental toxicity 
Gestation days 
9 – 14 
Maternal: 0.8 ml/kg 
Foetal: 0.8 ml/kg 
 
(Hasegawa and Toda, 1978) 1. 
The test substance was 
Rowachol®, a mixture of 
α/β-pinene (17 %), l-menthol 
(32 %), menthone (6 %), 
borneol (5 %), d-camphene 
(5 %), 1,8-cineole 
(eucalyptol) (2 %), and 
rheochrysin (0.1 %). 
(Phenoxyacetic acid [08.049]) Mouse / F  
11 / 8 or more 
Gavage Single dose of 800-900 
mg/kg bw on on of days  
8 - 15 of gestation 
or  
three doses of 250 - 300 
mg/kg bw at gestation 
days 7 - 9, 10 - 12 or 13 
- 15 
Developmental toxicity: 
One dose (Gestation days 8 - 15) or  
three doses  
(Gestation days 7 - 9, 10 - 12 or 13 - 15) 
Maternal: NR  
Foetal: 300 and 900 
(Hood et al., 1979) 2. 
F = Female. 
NR = Not reported. 
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
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Table 13:  Genotoxicity (in vitro) 
In vitro mutagenicity/genotoxicity data are available for three candidate substances of the present Flavouring Group Evaluation and for 15 supporting 
substances evaluated by the JECFA at the 51st, 59th and 61st meeting (JECFA, 1999a; JECFA, 2003a; JECFA, 2004b). Supporting substances are listed in 
brackets. 
TABLE 13: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(Anisole [04.032]) Ames reverse mutation 
assay 
(plate incorporation method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
 (+/- S9) 
(Florin et al., 1980) 2. 
 Sister chromatid exchange Human lymphocytes 0 - 2 mM Negative 
 (-S9 only) 
(Jansson et al., 1988) 2. 
(1-Methoxy-4-methylbenzene 
[04.015]) 
Ames reverse mutation 
assay 
(plate incorporation method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
Published non-GLP study. Limited report of study 
details. Validity of the study cannot be evaluated. 
 Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
50 mg/plate Negative 
(+/- S9) 
(Heck et al., 1989) Published non-GLP study. Some important details of 
study design and results are not reported. Thus, the 
validity of the study cannot be evaluated. 
 Unscheduled DNA 
synthesis 
Rat hepatocytes 188 µg/ml Positive (Heck et al., 1989) 2. 
Published non-GLP study. No information 
concerning the number of concentrations tested. Due 
to the lack of some important details of study design 
and results the validity of the study cannot be 
evaluated. 
(1,2-Dimethoxybenzene [04.062]) Ames reverse mutation 
assay 
S. typhimurium  
TA100 
0.1, 1, 10 and 1000 
µg/plate 
Negative (Rapson et al., 1980) 2. 
(1,3-Dimethoxybenzen [04.016]) Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
3.6 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
(1,4-Dimethoxybenzene [04.034]) Ames reverse mutation 
assay (preincubation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
10 - 900 µg/plate Negative 
(+/- S9) 
(Haworth et al., 1983) 2. 
 Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
5000 ng/plate Negative 
(+/- S9) 
(CIT)  
1,2,3-Trimethoxybenzene [04.084] Ames reverse mutation 
assay  
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) Tested quantitatively with TA100. Published non-
GLP study. Limited report of study details. No 
results reported. Validity of the study cannot be 
evaluated. 
 SOS Chromotest E. coli PQ37 NR Negative (Ohshima et al., 1989) Study assessing the SOS-inducing potency of a range 
of phenols after nitrosation in vitro in the absence of 
metabolic activation. The result for 1,2,3-
trimethoxybenzene was negative. 
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TABLE 13: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(1,8-Cineole [03.001]) Ames reverse mutation 
assay 
S. typhimurium TA97, TA98, 
TA100, TA102 
250 - 2500 µg/plate Negative 
(+/- S9) 
(Gomes-Carneiro et al., 
1998) 
2. 
Published non-GLP study. Fairly detailed description 
of study details and results, generally follows OECD 
guidelines. Study considered valid. 
 Ames reverse mutation 
assay (preincubation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3.3 - 3333 µg/plate Negative 
(+/- S9) 
(Haworth et al., 1983) 2. 
Published summary report including detailed results 
from studies on 250 compounds tested in various 
laboratories within the NTP to a large extent in 
accordance with OECD Guideline 471. 
 Sister chromatid exchange Chinese hamster ovary cells 50 - 500 µg/ml 
600 - 800 µg/ml 
Positive (-S9) 
Negative (+S9) 
(Galloway et al., 1987) 2. 
Lowest dose to give a significant increase in SCE: 
Trial I – 500 µg/ml; Trial II – 200 µg/ml. Published 
non-GLP study. Doses were selected based on 
preliminary assay.  Some details of results are not 
reported. Test was positive only without activation 
and at doses that induced cell cycle delay. 
 Sister chromatid exchange Chinese hamster ovary K-1 
cells 
10, 33.3 and 100 µM Negative 
(-S9 only) 
(Sasaki et al., 1989) 2. 
Published non-GLP study of limited quality. Study 
designed to investigate the influence on spontaneous 
as well as on mitomycin-induced SCEs. 
 Chromosomal aberration 
assay 
Chinese hamster ovary cells 479 - 663 µg/ml 
630 - 810 µg/ml 
Negative  
(+/- S9) 
(Galloway et al., 1987) 2. 
Published non-GLP study. Doses were selected 
based on preliminary assay. Although some details of 
results are not reported the study is considered valid. 
No aberration induction was detected even after 
extending the incubation time without S9 to 20 hours. 
 Rec assay B. subtilis H17 (rec+) and 
M45 (rec-) 
18 µg/disk Negative (Oda et al., 1979) 2. 
Study published in Japanese without English abstract. 
Data extracted from tables. Validity of the study 
cannot be evaluated. The SOS chromotest is not 
considered predictive for genotoxicity. 
 Rec assay B. subtilis H17 (rec+) and 
M45 (rec-) 
20 µl/disk  
(20,000µg/disk) 
Negative (Yoo, 1986) 2. 
Study published in Japanese with English abstract. 
Data extracted from tables. Validity of the study 
cannot be evaluated. The SOS chromotest is not 
considered predictive for genotoxicity. 
(1-Methoxy-4-propylbenzene 
04.039]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
750 µg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
 Unscheduled DNA 
synthesis 
Rat hepatocytes 5 x 10-3 M Negative (Howes et al., 1990) 2. 
(2-Methoxynaphthalene [04.074]) Ames reverse mutation 
assay 
(plate incorporation method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
(beta-Naphthyl ethyl ether [04.033]) Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
3.6 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
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TABLE 13: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
TA1538 
 Ames reverse mutation 
assay 
(plate incorporation method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
(Isobutyl beta-naphthyl ether 
[04.054]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
1 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
(2-Phenoxyethyl isobutyrate 
[09.487]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
3600 µg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 3. 
(Phenoxyacetic acid [08.049]) Mutagenicity assay S. cerevisiae  D7tsl 16 mM Negative  
(- S9) 
(Venkov et al., 2000)  
(Alpha-terpineol [02.014]) Ames test S. typhimurium 
TA98, TA100, TA1535, 
TA1537, TA1538 
10000 µg/plate Negative (Heck et al., 1989) 4. 
 Ames test S. typhimurium 
TA97a, TA98, TA100, 
TA102 
2500 µg/plate Negative1 (Gomes-Carneiro et al., 
1998) 
 
 Ames test S. typhimurium 
TA98, TA100, TA1535, 
TA1537, TA1538 
1000 µg/plate Negative 
(+/- S9) 
(National Cancer Institute, 
1983) 
4. 
 Spot test S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µg/plate 
(463 µg/plate) 
Negative 
(+/- S9) 
(Florin et al., 1980) 4. 
 Mammalian cell mutation Mouse Lymphoma  
L5178Y TK +/- 
0.5 µl/ml (467µg/ml) 
0.75µl/ml (700 µg/ml) 
Negative (- S9) 
Negative (+S9) 
(Kirby et al., 1984)  
 Mammalian cell mutation Mouse Lymphoma  
L5178Y TK +/- 
300 nl/ml (280 µg/ml)  
250 nl/ml (233 µg/ml) 
Negative 
(+ S9) 
(Heck et al., 1989) 4. 
 Rec assay S. cerevisiae NR Negative (Oda et al., 1979) 4. 
(Terpineol acetate [09.830]) Rec assay B. subtilis  
H17, M45 
19 µg Negative (Oda et al., 1979) 4. 
Vanillin 3-(l-menthoxy)propane-
1,2-diol acetal [02.248] 
Ames test S. typhimurium  
TA98, TA100, TA1535, 
TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Kajiura, 1996) The study is not completely in accordance with 
OECD Guidelines 471: no confirmation of negative 
findings in an independent experiment and only two 
plates per concentration. 
 Ames test E. coli WP2 uvrA Up to 5000 µg/plate Negative 
(+/- S9) 
(Kajiura, 1996) The study is not completely in accordance with 
OECD Guidelines 471: no confirmation of negative 
findings in an independent experiment and only two 
plates per concentration. 
5-Isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran 
[13.200] 
 S. typhimurium  
TA98, TA100,TA102, 
TA1535, TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Thompson, 2008) Valid GLP study. 
 
(Tetrahydro-4-methyl-2-(2-
methylpropen-1-yl)pyran [FL-no: 
13.037) 
 S. typhimurium  
TA98, TA100,TA102, 
TA1535, TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Verspeek-Rip, 2002) Valid GLP study. 
1 A slight but dose-related response was noted with TA102 with and without the use of metabolic activation.  
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2 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
3 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
4 Summarised by JECFA 51st  meeting (JECFA, 1999a). 
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Table 14:  Genotoxicity (in vivo) 
In vivo mutagenicity/genotoxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation but for six supporting 
substances evaluated by the JECFA at the 59th and 61st meeting (JECFA, 2003a; JECFA, 2004b). Supporting substances are listed in brackets. 
TABLE 14: GENOTOXICITY (IN VIVO) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(1,3-Dimethoxybenzene [04.016]) In vivo Micronucleus test Mouse Intraperitoneal 
injection 
558, 966 or 1382 mg/kg bw Negative (Wild et al., 1983) 1. 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM Negative (Wild et al., 1983) 1. 
In vivo Micronucleus test Mouse Oral gavage 2000 mg/kg bw Negative (Hoechst, 1996)  
(1,4-Dimethoxybenzene [04.034]) 
 
In vivo Micronucleus test Mouse Intraperitoneal 
injection 
750, 1125 or 1500 mg/kg Negative (Wild et al., 1983)  
(1-Methoxy-4-propylbenzene 
[04.039]) 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster (751 µg/ml) 5 mM Negative 
(+/- S9) 
(Wild et al., 1983) 1. 
In vivo Micronucleus test Mouse Intraperitoneal 
injection 
1500 mg/kg Negative 
 
(Wild et al., 1983) 1. 
(beta-Naphthyl ethyl ether [04.033]) In vivo Micronucleus test Mouse Intraperitoneal 
injection 
344, 603 or 861 mg/kg bw Negative (Wild et al., 1983) 1. 
 In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM Negative (Wild et al., 1983) 1. 
(Isobutyl beta-naphthyl ether 
[04.054]) 
In vivo Micronucleus test Mouse Intraperitoneal 
injection 
800, 1400 or 2000 mg/kg bw Negative (Wild et al., 1983) 1. 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM  Negative (Wild et al., 1983) 1. 
(2-Phenoxyethyl isobutyrate [09.487]) In vivo Micronucleus 
formation assay 
Mouse bone marrow 
cells 
Intraperitoneal 
injection 
1875 mg/kg/bw Negative (Wild et al., 1983) 2. 
In vivo Sex-linked 
recessive mutation 
D. melanogaster  10 mM  Negative (Wild et al., 1983)  
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
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ANNEXES 
ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in 
schematic form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on 
Food expressed on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure 
developed by the Joint FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th 
meetings (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in 
the Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which 
thresholds of concern (human exposure thresholds) have been specified. Exposures below these 
thresholds are not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, 
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural 
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that 
have structural features that permit no strong initial presumption of safety, or may even suggest 
significant toxicity (Cramer et al., 1978). The thresholds of concern for these structural classes of 
1800, 540 or 90 microgram/person/day, respectively, are derived from a large database containing 
data on subchronic and chronic animal studies (JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products9
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
 (Step 2)?  
• are the flavourings or their metabolites endogenous10
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and 
B4)? 
 (Step A4)?  
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with 
the results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted 
such actions. 
 
                                                     
9 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated 
intakes of the flavouring agent” (JECFA, 1997). 
10 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004b). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 – 15.0 
 
The “normal and maximum use levels” are provided by Industry for all candidate substances in the 
present flavouring group (EFFA, 2003a; EFFA, 2004a; EFFA, 2004c; EFFA, 2007a; EFFA, 2012; 
Flavour Industry, 2006; Flavour Industry, 2008; Flavour Industry, 2009; Flavour Industry, 2010; 
Flavour Industry, 2011) (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.23Rev 4 (EFFA, 2003a; EFFA, 
2004a; EFFA, 2004c; EFFA, 2007a; EFFA, 2012; Flavour Industry, 2006; Flavour Industry, 2008; Flavour Industry, 
2009; Flavour Industry, 2010; Flavour Industry, 2011). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.247 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.248 - 
- 
2 
5 
- 
- 
- 
- 
5 
10 
10 
20 
5 
20 
5 
20 
- 
- 
2 
10 
- 
- 
- 
- 
10 
20 
- 
- 
2 
10 
2 
10 
- 
- 
10 
20 
03.008 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
15 
75 
3 
15 
10 
50 
- 
- 
5 
25 
03.011 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.012 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.015 3 
15 
2 
10 
3 
15 
3 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.016 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.020 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.022 0,0015 0,0015 0,015 0,0015 0,0015 0,15 - 0,015 0,0015 0,0015 - - 0,0015 - 0,15 0,15 0,0015 0,0015 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.23Rev 4 (EFFA, 2003a; EFFA, 
2004a; EFFA, 2004c; EFFA, 2007a; EFFA, 2012; Flavour Industry, 2006; Flavour Industry, 2008; Flavour Industry, 
2009; Flavour Industry, 2010; Flavour Industry, 2011). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
0,0125 0,0125 0,125 0,0125 0,0125 1,25 - 0,125 0,0125 0,0125 - - 0,0125 - 1,25 1,25 0,0125 0,0125 
03.024 - 
- 
- 
- 
50 
100 
- 
- 
- 
- 
70 
100 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
15 
30 
30 
60 
- 
- 
50 
100 
04.059 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.067 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.068 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.069 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.075 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.079 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.084 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.127 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
09.687 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.170 1,01 
2,03 
- 
- 
- 
- 
- 
- 
- 
- 
3,22 
6,72 
- 
- 
2,5 
4 
- 
- 
- 
- 
- 
- 
- 
- 
0,02 
0,05 
- 
- 
0,53 
0,78 
0 
0 
- 
- 
- 
- 
13.200 0,5 
5 
0,5 
10 
0,1 
10 
0,5 
10 
0,5 
10 
1 
50 
5 
10 
1 
5 
- 
- 
- 
- 
0,5 
5 
1 
50 
1 
10 
- 
- 
0,1 
5 
0,5 
5 
- 
- 
- 
- 
 
The candidate substances [FL-no. 02.248, 13.170 and 13.200] are also anticipated to be used in 
chewing gum, which is not covered by any of the food categories. Normal/maximum use levels for 
chewing gum are reported to be 10/20 mg/kg for [FL-no: 02.248], 5/10 mg/kg for [FL-no:13.170] and 
50/1000 mg/kg for [FL-no:13.200]. For chewing gum, the intake estimate is 2 g/day. It is anticipated 
that all of the flavouring substance is released from the chewing gum. In the calculation of the 
mTAMDI of these candidate substances, use level figures in Table II.1.2 and the use level of chewing 
gum ((use level of chewing gum in mg/kg) x (2 g daily intake of chewing gum) = mg/person/day) are 
summed up to a total mTAMDI value of 2500 µg/person/day for [FL-no: 02.248], 600 µg/person/day 
for [FL-no: 13.170] and 860 µg/person/day for [FL-no: 13.200]. These values are presented in table 
II.2.3 and 5. 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table II.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 
16 (EC, 2000) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed 
in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the flavouring substances in the 
present flavouring group (EFFA, 2003a; EFFA, 2004a; EFFA, 2004c; EFFA, 2007a; EFFA, 2012; 
Flavour Industry, 2006; Flavour Industry, 2008; Flavour Industry, 2009; Flavour Industry, 2010; 
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Flavour Industry, 2011). The mTAMDI values are only given for highest reported normal use levels 
(see Table II.2.3). 
Table II.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(µg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
04.059 Carvacryl methyl ether 3200 Class I 1800 
04.084 1,2,3-Trimethoxybenzene 3200 Class I 1800 
03.008 2-Acetoxy-1,8-cineole 3500 Class II 540 
03.011 Benzyl methyl ether 3200 Class II 540 
03.012 Benzyl octyl ether 3200 Class II 540 
03.015 Ethyl geranyl ether 3200 Class II 540 
03.016 Hexyl methyl ether 3200 Class II 540 
03.024 Digeranyl ether 14000 Class II 540 
04.079 Methyl-4-methoxybenzyl ether 3200 Class II 540 
02.247 l-Menthoxyethanol 3900 Class III 90 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol acetal 2500 Class III 90 
03.020 alpha-Terpinyl methyl ether 3200 Class III 90 
03.022 1-Methoxy-1-decene 58 Class III 90 
04.067 1-Ethoxy-2-methoxybenzene 3200 Class III 90 
04.068 1-Ethoxy-4-methoxybenzene 3200 Class III 90 
04.069 1-Ethyl-4-methoxybenzene 3200 Class III 90 
04.075 1-Methoxynaphthalene 3200 Class III 90 
08.127 2-(4-Methoxyphenoxy)propionic acid 3200 Class III 90 
09.687 2-Phenoxyethyl butyrate 3900 Class III 90 
13.170 2S-cis-Tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-
pyran 
600 Class III 90 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran 860 Class III 90 
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ANNEX III: METABOLISM 
III.1. Introduction 
The candidate substances are examples of aliphatic, alicyclic or aromatic ethers. On the basis of their 
structure they can be divided into seven subgroups:  
1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022],  
2) alicyclic ethers [FL-no: 03.008, 13.170 and 13.200],  
3) alicyclic hydrocarbons with an ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-
no: 02.248] has an acetal moiety,  
4) benzyl ethers [FL-no: 03.011 and 03.012],  
5) phenol ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687],  
6) naphthol ethers [FL-no: 04.075] and  
7) long chain aliphatic ethers [FL-no: 03.024] (see Table III.1). 
Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
1 Aliphatic Ethers 
03.015 Ethyl geranyl ether 
O  
 
03.016 Hexyl methyl ether O   
03.022 1-Methoxy-1-decene   O
 
 
(03.005) (2-Butyl ethyl ether) O
 
 
(03.006) (2-Methoxyethyl benzene) O
 
 
(03.019) (Prenyl ethyl ether) O
 
 
2 Alicyclic Ethers 
03.008 2-Acetoxy-1,8-cineole 
O
O
O
 
 
13.170 2S-cis-Tetrahydro-4-methyl-2-(2-methyl-1-
propenyl)-2H-pyran 
O
 
 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
O
 
 
(03.001) (1,8-Cineole) 
O
 
 
(03.007) (1,4-Cineole) 
O
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
(13.037) (2-(2-Methylprop-1-enyl)-4-
methyltetrahydropyran) 
O
 
 
(13.088) (3,6-Dihydro-4-methyl-2-(2-methylprop-1-en-
1-yl)-2H-pyran) 
O
 
 
(13.094) (2,6,6-Trimethyl-2-vinyltetrahydropyran) 
O  
 
3 Alicyclic Hydrocarbons with Ether Side Chain 
02.247 l-Menthoxyethanol 
O
OH
 
 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
O
O
O
OHO  
 
03.020 alpha-Terpinyl methyl ether  
O
 
 
(02.014) (alpha-Terpineol) 
HO  
 
(09.830) (Terpineol acetate) 
O O  
 
4 Benzyl Ethers 
03.011 Benzyl methyl ether O
 
 
03.012 Benzyl octyl ether O
 
 
(03.003) (Benzyl ethyl ether) O
 
 
(03.010) (Benzyl butyl ether) 
O
 
 
5 Phenol Ethers 
04.059 Carvacryl methyl ether 
O
 
 
04.067 1-Ethoxy-2-methoxybenzene O
O  
 
04.068 1-Ethoxy-4-methoxybenzene 
O
O
 
 
04.069 1-Ethyl-4-methoxybenzene 
O  
 
04.079 Methyl 4-methoxybenzyl ether O
O  
 
04.084 1,2,3-Trimethoxybenzene 
O O
O
 
 
08.127 2-(4-Methoxyphenoxy)propionic acid O
O
OH
O  
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
09.687 2-Phenoxyethyl butyrate 
O
O
O
 
 
(04.014) (1-Methoxy-2-methylbenzene) O
 
 
(04.015) (1-Methoxy-4-methylbenzene) 
O
 
 
(04.016) (1,3-Dimethoxybenzene) 
O
O
 
 
(04.032) (Anisole) 
O
 
 
 
(04.034) (1,4-Dimethoxybenzene) 
OO
 
 
 
(04.038) (Carvacryl ethyl ether) 
O
 
 
(04.039) (1-Methoxy-4-propylbenzene) O
 
 
(04.040) (1,2-Dimethoxy-4-vinylbenzene) 
O
O
 
 
(04.043) (1-Isopropyl-2-methoxy-4-methylbenzene) 
O
 
 
(04.062) (1,2-Dimethoxybenzene) OO
 
 
(04.063) (1,3-Dimethyl-4-methoxybenzene) 
O
 
 
(08.049) (Phenoxyacetic acid) 
O
OH
O
 
 
(09.487) (2-Phenoxyethyl isobutyrate) 
O
O
O  
 
6 Naphthol Ethers 
04.075 1-Methoxynaphthalene 
O
 
 
(04.033) (beta-Naphthyl ethyl ether) O
 
 
(04.054) (Isobutyl beta-naphthyl ether) 
O
 
 
(04.074) (2-Methoxynaphthalene) O
 
 
7 Long Chain Aliphatic Ether 
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
03.024 Digeranyl ether 
O
 
 
 
No toxicokinetic studies were found on the candidate substances. Data on absorption, distribution and 
excretion are available for supporting substances and are described below. 
III.2. Absorption, Distribution and Elimination 
The aliphatic ethers are expected to be rapidly absorbed from the gastrointestinal tract and excreted. 
Subgroup 1: Aliphatic Ethers [FL-no: 03.015, 03.016 and 03.022] 
Data on absorption, metabolism and urinary excretion of the aliphatic ethers in animals are available 
for the structurally-related substance methyl tertiary-butyl ether (MTBE). MTBE is completely 
absorbed, metabolised and excreted following oral administration of 40 mg/kg bw to rats. MTBE was 
totally absorbed by the Gastrointestinal (GI) tract (as demonstrated by the identical Area Under the 
Curve (AUC) value calculated after oral and intravenous administration); the peak plasma 
concentration was reached within 15 minutes. It was then rapidly eliminated from the blood, with a 
reported half-life of 30 minutes, by exhalation as such (> 60 % of the administered dose) and 
metabolism to tertiary-butyl alcohol, which is mainly excreted into the urine (blood half-life =1 - 2 
hours). At a higher dose (400 mg/kg bw), metabolism was saturated and the proportion of renal [14C] 
excretion decreased relatively to the pulmonary route of elimination. At 48 hours post exposure, 
almost all the administered radioactivity was eliminated at both doses. No tissue-specific affinity or 
gender differences were described in the toxicokinetics and distribution of MTBE (Miller et al., 
1997). 
After the oral administration of 200 mg/kg bw 1,8-cineole [FL-no: 03.001] (synonym: eucalyptol) to 
rabbits, peak plasma concentration of the parent compound occurred within 30 minutes and reached a 
maximum plasma level of 840 μg/dl, while the plasma level of the principal unconjugated metabolite, 
(+)-2-endo-hydroxy-1,8-cineole, peaked at 2400 μg/dl within one hour post exposure and then 
decreased slowly between two and six hours. Peak plasma levels (1250 μg/dl) of the major conjugated 
metabolite, the glucuronide of (+)-2-exo-hydroxy-1,8-cineole, occurred within 1.5 to 2 hours after 
dosing (Miyazawa et al., 1989).  
Subgroup 2: Alicyclic Ethers [FL-no: 03.008, 13.170 and 13.200] 
When 4, 20 or 40 μl of rosemary oil as a oil/water emulsion, containing 39 % 1,8-cineole 
(approximately equivalent to 52, 260, and 520 mg/kg bw of 1,8-cineole, respectively) were 
administered orally to mice, blood levels of the parent compound reached a peak level 5 minutes 
following the exposure. At 260 mg/kg bw, blood levels remained fairly constant over the following 90 
minutes. At 520 mg/kg bw, the peak blood concentration dropped to 60 % of the maximum value and 
remained in that range for the following 80 minutes (Kovar et al., 1987). These results indicate that at 
doses up to 200 mg/kg, 1,8-cineole is rapidly absorbed into the blood, and eliminated by conjugation 
to polar metabolites. At higher doses, metabolism appears to be slower, due to saturation of the 
metabolic pathway.  
In humans, data are available for the inhalation route. In four healthy volunteers exposed for twenty 
minutes to air passing over 4 ml of 1,8-cineole via a closed breathing circuit, 1,8-cineole showed 
biphasic elimination from the blood. The peak blood concentration was reached within 15 minutes in 
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all the subjects, attaining similar values (about 460 - 1100 ng/ml), indicating small inter-individual 
differences in the absorption phase. The mean half-life for distribution was 6.7 minutes, whereas the 
half-life for elimination is 104.6 minutes. However, 1,8-cineole distribution seemed to be affected by 
the body composition of the volunteer (Jäger et al., 1996).  
Terpenes are rapidly absorbed in the GI tract and due to their lipophilicity are extensively distributed 
in the body. Using radio-labelled citral (3,7-dimethyl-2,6-octadienal), it was shown that in rats, 14C is 
widely distributed within 72 hours and citral is probably metabolised through various pathways to 
common biological metabolites which are incorporated into tissues. This however, constitutes only a 
very small proportion of the dose administered. Following oral administration of citral in rats, 67 % of 
the 5 mg/kg bw dose was excreted within 24 hours, 45 % of this was excreted in the urine. Radio-
labelled metabolites appeared within 2 hours of administration (Diliberto et al., 1988).  
Subgroup 3: Alicyclic Hydrocarbons with Ether Side Chain [FL-no: 02.247, 02.248 and 03.020] 
Following administration of 5 mg/kg bw of citral in rats, 95 % was excreted within 24 hours. The 
majority of this dose (60 %) was excreted in the urine, 20 % was excreted in the lungs as 14CO2 and 
17 % was excreted in the faeces. A very small proportion (0.5 %) of 14C found in the urine was found 
to be unchanged citral and 1.5 % of the total 14C was retained in the liver. At higher levels (960 mg/kg 
bw), between 60 % and 70 % of the 14C was excreted within 24 hours. Again, this was mostly 
excreted in the urine (47 %). However, a lower level was excreted as 14CO2. Faecal excretion was 
much more delayed than at lower doses up to 36 hours after administration and the rate of faecal 
elimination increased between 36 and 96 hours following administration. Ninety-five % of the total 
14C was eliminated within 96 hours. The identities of the metabolites were not determined in this 
study, however, they were shown to be polar hexane-insoluble unsaturated compounds (Phillips et al., 
1976). 
Aromatic ethers containing a benzene ring are thought to be absorbed, distributed and excreted in a 
similar way as alkylbenzenes.  
Subgroup 4: Benzyl Ethers [FL-no: 03.011 and 03.012] 
On administration of n-propylbenzene to chinchilla rabbits, approximately 60 - 70 % was excreted in 
the urine within 24 hours as conjugates of glucuronide and hippuric acid. Ethylphenylcarbinyl 
glucosiduronic acid was readily isolated from the urine of these rabbits (El Masry et al., 1956). In the 
same study, about 50 % of the administered dose of butylbenzene was shown to be excreted as the 
glucuronides of methyl-2-phenylethylcarbinol and phenylpropylcarbinol and around 20 % was 
excreted as phenaceturic acid. Approximately 4 % was excreted as hippuric acid. 
Following administration of 5 ml/kg bw of n-propylbenzene, the urinary sulphate ratio of 
inorganic/total sulphate was reduced considerably between 24 and 72 hours. The sulphate ratio 
returned to normal after 96 hours. An increase in alkyl chain length was shown to be associated with 
an increase in the time taken for the sulphate ratio to return to normal, which indicates an increase in 
the time taken to eliminate the substance from the body (Gerarde and Ahlstrom, 1966). 
Alkylbenzenes appear to be metabolised to innocuous products and excreted as conjugates of 
glucuronides and as hippuric acid in the urine.  
When the supporting substance anisole [FL-no: 04.032] (500 mg/kg bw) was administered to rabbits 
via stomach tube, about 80 % of the dose was excreted in the urine within 24 hours, mainly as the 
products of p-hydroxylation and the corresponding glucuronide and sulphate. The unchanged ethers 
Subgroup 5: Phenol Ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 
09.687] 
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were not detected in the urine and no smell of anisole was detected in the breath of the rabbits (Bray 
et al., 1953). 
The majority (up to about 70 %) of I-methylanisole administered via gavage to six rabbits was 
excreted in the urine within 24 hours after oxidation to anisic acid and subsequent glucuronidation 
and as p-cresol (the latter metabolite accounting for about 27 % of the administered dose) (Bray et al., 
1955).  
When a single dose of [14C]-p-propylanisole (labelled at the methoxy position) was administered to 
female Wistar albino rats via oral intubation and to male CD-1 mice via the intraperitoneal route at 
dose levels of 0.05, 0.5, 5, 50, 500 or 1500 mg/kg bw, at the lowest dose level the majority of 
radioactivity was excreted as 14CO2 in the expired air (81.6 and 74.5 % in rats and mice, respectively), 
whereas the urinary excretion accounted for 8.0 and 15.0 % in rats and mice, respectively. As dose 
levels increased up to 1500 mg/kg bw, approximately equal amounts were excreted in the urine (37.1 
and 38.0 % in rats and mice, respectively) and in the expired air as 14CO2 (47.2 and 49.9 % in rats and 
mice, respectively) within 72 hours, suggesting that the O-demethylation pathway becomes saturated 
at the higher dose levels. Approximately 1 - 5 % was excreted in the faeces regardless of the 
administered dose. However, in all the experimental conditions tested, more than 80 % of the 
administered dose was excreted within 72 hours after the treatment (Sangster et al., 1983).  
Approximately 67 % of a 100 μg dose of [14C]-methoxy-labelled p-propylanisole administered by 
gelatin capsule to two humans was recovered within 8 hours, the majority of which (43 %) in the 
expired air and the remainder (about 24 %) in the urine (Sangster et al., 1987).  
After absorption, the supporting substance beta-naphthyl methyl ether [FL-no: 04.033] is 
hydroxylated and excreted as a glucuronide (Williams, 1959). 
Subgroup 6: Naphthol Ethers [FL-no: 04.075] 
No data are available on the absorption, distribution and excretion of the substance in this sub-group 
or any supporting substances but as with the other substances in this flavouring group, digeranyl ether 
[FL-no: 03.024] would be expected to be rapidly absorbed from the gastrointestinal tract. 
Dealkylation of ethers becomes less likely as the chain length increases and ω-oxidation is more likely 
to occur (Tsuji et al., 1978). For geraniol, next to other pathways of metabolism related to the 
presence of a free hydroxyl-group, ω-oxidation has also been described and this would result in 
metabolism to innocuous products. As digeranyl ether [FL-no: 03.024] contains no free hydroxyl 
group like geraniol, the other pathways for metabolism of geraniol are not available for digeranyl 
ether and therefore ω-oxidation is more likely to occur. 
It would be expected that following ω-oxidation, the metabolites would be conjugated with 
glucuronide and excreted as polar metabolites in the urine in a similar way to the aliphatic saturated 
tertiary alcohols found in FGE.18, Revision 1 (EFSA, 2009) and the non-polar hydrocarbons found in 
FGE.25 (EFSA, 2008). 
Subgroup 7: Long Chain Aliphatic Ether [FL-no: 03.024] 
III.3. Metabolism 
No metabolism studies were found for the candidate substances. 
Several metabolic options are available to aliphatic and aromatic ethers. One pathway for aliphatic 
and aromatic ethers is O-dealkylation to form the corresponding aldehydes and alcohols if a suitable 
alkyl substituent (methyl or ethyl) is attached to the ether oxygen. The resulting alcohols may be 
further oxidised followed by conjugation and excretion, while the aldehydes (i.e. acetaldehyde and 
formaldehyde) are oxidised to carboxylic acids, which participate in fundamental biochemical 
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pathways, including the fatty acid pathway and tricarboxylic acid cycle, resulting in CO2 expiration. 
Alternatively, the aliphatic acyclic or aromatic moiety may undergo cytochrome P450-catalysed C-
oxidation (ring-hydroxylation or side-chain oxidation), followed by conjugation with sulphate or 
glucuronic acid and then excretion, mainly via the urinary route. 
Aliphatic ethers included in the present evaluation are expected to undergo NADPH-dependent P450-
catalysed O-dealkylation to the corresponding alcohols and aldehydes.  
Subgroup 1: Aliphatic Ethers [FL-no: 03.015, 03.016 and 03.022] 
In vitro, by using liver microsomes from Sprague-Dawley rats, methyl tertiary-butyl ether (MTBE) 
was O-demethylated to form almost equal amounts of t-butyl alcohol (TBA) and formaldehyde (Brady 
et al., 1990). MTBE metabolism was inhibited 35 % by monoclonal antibodies to CYP2E1 and 
increased in acetone-induced microsomes, indicating that MTBE is partially metabolised by this P450 
isozyme. Pretreatment of rats via intraperitoneal injection with 1 or 5 ml MTBE/kg bw did not affect 
the activity of CYP2E1, but induced CYP2B1, suggesting that this CYP may be also involved in 
MTBE biotransformation (Brady et al., 1990).  
In vivo, oral administration of 40 mg/kg bw of MTBE to rats resulted in the rapid production of TBA. 
The alcohol was detected in the blood (half life = 1 - 2 hours) and in the urine. At a 10-fold higher 
dose, the metabolism appeared to be saturated, and a higher percentage of the administered dose was 
recovered as parental compound in the exhaled air (Miller et al., 1997). 
In other studies, methyl tertiary-butyl ether (MTBE) and ethyl tertiary-butyl ether were administered 
to rat by inhalation, while TBA, the major initial metabolite of the two ethers, was studied after oral 
gavage (250 mg/kg bw). Only minor amounts of TBA and its conjugate were detected in the urine of 
rats dosed with the ethers, whereas 2-methyl-1,2-propanediol, 2-hydroxyisobutyrate and an 
unidentified TBA conjugate were the major urinary metabolites. The same major metabolites were 
found in TBA-treated rats, being unchanged TBA, its glucuronide and acetone only detected in minor 
amounts. Similar results were obtained in one human volunteer, taking 5 mg/kg TBA orally, 
suggesting that TBA, formed by MTBE and ETBE, is extensively metabolised by further oxidation 
reactions (Bernauer et al., 1998). 
It has been reported that diethyl ether was biodegraded to 14CO2 in amounts of 1 to 5 % in rats (Krantz 
and Carr, 1969), due to its O-demethylation to ethanol and acetaldehyde, followed by oxidation to 
acetate, which eventually enters the citric acid cycle. This further supports the likelyhood that the 
candidate aliphatic ethers may undergo O-dealkylation to form their corresponding alcohols and 
aldehydes, which are expected to subsequently participate in the fatty acid pathway and tricarboxylic 
acid cycle. 
The anticipated demethylated product of 1-methoxy-1-decene [FL-no: 03.022] is an enol, which will 
rearrange to the aldehyde, which subsequently can be oxidised to the carboxylic acid. 
In humans and other animals, alicyclic ethers, such as the supporting substances 1,4-cineole [FL-no: 
03.007] and 1,8-cineole [FL-no: 03.001], have been shown to be oxidised via P450 isoenzymes to 
yield polar hydroxylated metabolites, which are conjugated and excreted or further oxidised and 
excreted. Cleavage of the ether is, at most, a very minor metabolic pathway (Hiroi et al., 1995; 
Miyazawa et al., 2001a; Miyazawa et al., 2001b; Miyazawa and Shindo, 2001). 
Subgroup 2: Alicyclic Ethers [FL-no: 03.008, 13.170 and 13.200]  
The metabolism of 1,8-cineole [FL-no: 03.001] has been studied in various animal species. It has been 
reported that 1,8-cineole principally undergoes ring-hydroxylation to form 2- or 3-hydroxy-1,8-
cineole, which are subsequently excreted as the glucuronic acid conjugates (Williams, 1959) (see 
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Figure III.1). Indeed, following the gavage administration of 800 mg 1,8-cineole/kg bw to male albino 
rats, major metabolites included 2- and 3-hydroxy-1,8-cineole and their conjugates and 1,8-dihydroxy-
10-carboxy-p-menthane, which were hypothesised to be formed by the oxidation of the metabolite p-
menthane-1,8-diol formed by cleavage of the ether linkage (Madyastha and Chadha, 1986).  
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Figure III.1  Metabolism of 1,8-cineole (eucalyptol) in rats and humans. 
These results are consistent with a more recent study, in which 1,8-cineole [FL-no: 03.001] 
metabolism in microsomes from male Hooded Wistar rats and humans was studied (Pass et al., 2001). 
To determine the effect on the efficiency of biotransformation, expressed as the intrinsic clearance 
(Vmax/Km) of the reaction, caused by possible induction of metabolism, rats were pre-treated daily for 
six days with a mixture of terpenes (255 mg 1,8-cineole/kg bw; 4 mg p-cymene/kg bw; 34 mg 
limonene/kg bw; 103 mg α-pinene/kg bw) by gavage, or 80 mg/kg bw of phenobarbital (PB). Liver 
microsomes prepared from pre-treated and control rats, as well human liver microsomes pooled from 
seven male patients were incubated with 5 - 200 μM 1,8-cineole. Intrinsic clearance values were 27.5, 
258.2, 1824.7 and 11.6 μl⋅mg protein-1⋅minute-1 in microsomes from control, terpene-treated, PB-
treated rats and humans, respectively. The efficiency in 1,8-cineole metabolism was similar in control 
rat and human microsomes, whereas terpenes and, at a higher extent, PB-induced rat microsomes 
metabolised 1,8-cineole more efficiently. This result suggests that terpenes are able to induce their 
own metabolism, in which CYP2B1 (induced by PB) is very likely involved (Pass et al., 2001). 
Although with differences in their relative amounts, qualitatively the various liver microsomes 
produced the same hydroxylated metabolites. Control rat microsomes produced 3-hydroxy-1,8-cineole 
as the major metabolite, followed by 2- and 9-hydroxycineole. Microsomes from terpene-treated rats 
produced similar amounts of 2- and 3-hydroxy-1,8-cineole and lesser amounts of 9-hydroxy-1,8-
cineole. Of the six metabolites detected in the microsomes from PB-treated rats, 2-hydroxy-1,8-
cineole was the major metabolite, followed by 3- and 9-hydroxy-1,8-cineole, whereas the remaining 
three metabolites consisted of trace amounts of 7-hydroxy-1,8-cineole, 9-cineolic acid and one 
unknown hydroxycineole metabolite. 2-Hydroxy-1,8-cineole was the major metabolite from pooled 
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human liver microsomes, while 9-hydroxy-1,8-cineole was the minor metabolite. The authors 
concluded that in rats and humans, oxidation was preferred at the aliphatic ring carbons over methyl 
substituents (Pass et al., 2001).  
The metabolism of 1,8-cineole [FL-no: 03.001] was studied in vivo in rabbits treated by gavage with 
200 mg/kg bw. The major metabolites were identified as 2- and 3-hydroxy-1,8-cineole (Miyazawa et 
al., 1989). When rat and human liver microsomes and recombinant human CYPs (i.e. c-DNA 
expressed in insect cells) were incubated in vitro with 1,8-cineole, it was oxidised at high rates to 2-
exo-hydroxy-1,8-cineole (see Figure III.1) (Miyazawa et al., 2001b; Miyazawa and Shindo, 2001). As 
indicated by results obtained with recombinant CYPs, P450 inducers (PB and pregnenolone 16-alpha-
carbonitrile) and specific P450 inhibitors, the reaction in humans is mainly catalysed by CYP3A2 and 
3A4 in rat and human liver microsomes, respectively (Miyazawa et al., 2001a; Miyazawa et al., 
2001b). Earlier studies also indicate that CYP3A family is induced by 1,8-cineole. Hepatic 
microsomes prepared from male Sprague-Dawley rats intraperitoneally injected 300 mg 1,8-
cineole/kg bw once a day for five days showed increased levels of 2B1 and 3A2 expression and in 
their related enzymatic activities (Hiroi et al., 1995). 
Hepatic microsomes from beta-naphthoflavone- or PB-pretreated female Wistar rats were used to 
investigate the inhibitory effects of 1,8-cineole [FL-no: 03.001] on the marker activities of CYP1A1 
(ethoxyresorufin-O-deethylase, EROD), 1A2 (methoxyresorufin-O-demethylase, MROD) and 2B1 
(pentoxyresorufin-O-depenylase, PROD). 1,8-Cineole caused no or negligible inhibition on EROD 
and MROD (up to 150 μM), while CYP2B1 activity was decreased in the presence of 1,8-cineole. The 
competion with the specific probe substrate for CYP2B1 indicates that also this isoform is involved in 
1,8-cineole metabolism in the rat (De-Oliveira et al., 1999). 
Oxidation of 1,4-cineole [FL-no: 03.007] was studied in rat and human liver microsomes as well as 
with recombinant human CYPs; in all cases the major identified metabolite was 2-exo-hydroxy-1,4-
cineole. 
Based on the results obtained with single recombinant isoforms on the effects of specific CYP 
inhibitors and antibodies and on the data from correlation studies, CYP3A4 was identified as the 
CYP, mainly responsible for 1,4-cineole oxidation. Similarly, CYP3A2 was active in the rat 
(Miyazawa et al., 2001a). 
In rabbits, 1,4-cineole [FL-no: 03.007] is metabolised by ring- and side-chain hydroxylation. Urinary 
metabolites collected over three days following administration of 10,000 mg 1,4-cineole/rabbit 
include the ring-hydroxylation product 3,8-dihydroxy-1,4-cineole, the side-chain hydroxylation 
product 9-hydroxy-1,4-cineole and its corresponding carboxylic acid, 1,4-cineole-9-carboxylic acid. 
Other metabolites included 8,9-dihydroxy-1,4-cineole and 1,4-cineole-8-en-9-ol. No evidence of ether 
cleavage was observed at this dose level (Asakawa et al., 1988). 
The available data on alpha-terpineol [FL-no: 02.014] as supporting substance for subgroup 3, suggest 
that the candidate substance [FL-no: 03.020] would be metabolised by P450 isoenzymes to yield polar 
hydroxylated metabolites, which are conjugated to form glucuronic acid conjugates and excreted or 
are further oxidised and excreted. Cleavage of the ether is a minor metabolic pathway (JECFA, 
1999a). The JECFA considered the metabolism of alpha-terpineol at their 51st meeting and they 
concluded that in humans and animals, terpenoid tertiary alcohols, of which alpha-terpineol is one, are 
conjugated primarily with glucuronic acid and are excreted in the urine and faeces. Unsaturated 
terpenoid alcohols may undergo allylic oxidation to form polar diol metabolites, which may be 
excreted either free or conjugated (Williams, 1959; Parke et al., 1974a; Parke et al., 1974b; Horning et 
al., 1976; Ventura et al., 1985). 
Subgroup 3: Cyclic Hydrocarbons with Ether Side Chain [FL-no: 02.247, 02.248 and 03.020] 
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Male albino rats were administered orally alpha-terpineol [FL-no: 02.014] (600 mg/kg bw) once daily 
for 20 days as a suspension (in 1 % methyl cellulose solution, 2 ml as final volume). The urinary 
metabolites were qualitatively identified. A significant amount of the test item was excreted 
unmetabolised and the allylic methyl oxidation was the major route of biotransformation. The 
reduction of the endocyclic double-bond was also seen. In addition, the treatment resulted in a 
substantial induction of P450-related activities in the liver (Madyastha and Srivatsan, 1988). 
Citral was shown to undergo first pass liver metabolism and also be metabolised by intestinal bacteria. 
Excretion of metabolites via the bile into the intestine results in enterohepatic recirculation of citral-
derived radioactivity (Diliberto et al., 1988). 
Citral has been shown to be metabolised to 7-carboxy-3-methylocta-2,6-dienoic acid and 7-carboxy-3-
methylocta-6-enoic acid (Williams, 1959). These are considered to be innocuous products. 
At low pH similar to that found in the stomach, vanillin 3-l-menthoxypropane-1,2-diol acetal [FL-no: 
02.248] is readily hydrolysed. In a hydrolysis study, 12 - 39 mM vanillin 3-l-menthoxypropane-1,2-
diol acetal underwent 91 % hydrolysis at pH 2 within 45 minutes. At pH 3, approximately 86 % of 
vanillin 3-l-menthoxypropane-1,2-diol acetal hydrolysed within 90 minutes. At a pH of 4, 
approximately 92 % of the acetal hydrolysed within 8 hours. At a pH of 5, approximately 12 % of the 
flavouring agent hydrolysed within 8 hours (Reitz, 1995). 
Under acidic conditions, pH 2.6, vanillin propylene glycol acetal began to hydrolyse immediately with 
approximately 3 % of the acetal disappearing and 92 % hydrolysed within two hours. At a pH of 1.8, 
approximately 90 % of vanillin propylene glycol acetal hydrolysed immediately and 93 % hydrolysed 
within five minutes (Bennett, 1997).  
As shown above vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] is shown to be 
hydrolysed to the corresponding ether and vanillin. It is expected that the alcohol groups in this ether 
subsequently are oxidised and that the carboxylic acid(s) are then excreted as such or after 
conjugation.  
Similarly, l-menthoxy-ethanol [FL-no: 02.247] is anticipated to be oxidised to the corresponding 
carboxylic acid and excreted. 
No data are available on the candidate substances, however, alkylbenzenes are considered to be 
metabolised in a similar way to benzyl ethers. Male albino rats were dosed with quantities of n-
propylbenzene and other alkylbenzenes at doses of up to 5 ml/kg. After dosing the animals were kept 
in metabolism cages and urine was collected in 24 hours fractions for 96 hours. Urine samples were 
analysed for organic and inorganic sulphates. The change in urinary sulphate ratio, inorganic/total was 
used to ascertain whether ring-hydroxylation had occurred after administration of increasing doses of 
alkylbenzenes. Following dosing with n-propylbenzene, it was shown that at 48 hours the peak level 
of excretion is reached and all of the n-propylbenzene is excreted by 96 hours following dosing at 5 
ml/kg bw. The authors conclude that alkylbenzenes with shorter side chains are primarily exhaled as 
unchanged hydrocarbon. As the side chain increases in size, the proportion of alkylbenzene that is 
ring-hydroxylated and excreted in the urine also increases. Organic sulphate in the urine indicates that 
ring-hydroxylation is occuring in the body to form phenol derivatives. The longer the alkyl side-chain, 
the greater the level of organic sulphate in the urine and therefore the greater the level of ring-
hydroxylation and production of phenol derivatives (Gerarde and Ahlstrom, 1966). 
Subgroup 4: Aromatic Ethers Containing a Benzene Ring [FL-no: 03.011 and 03.012]  
Following administration of n-propylbenzene, it was observed that the main product in the urine was 
ethyl phenyl carbinyl glucosiduronic acid. This shows that the major route of metabolism is via ethyl 
phenyl carbinol, which is then conjugated with glucuronic acid. Another route is via benzyl methyl 
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carbinol, which is more readily converted to hippuric acid. Another possible route is via omega-
oxidation to beta-phenylproprionic acid, which can be subsequently beta-oxidised to benzoic acid (El 
Masry et al., 1956). 
The supporting aromatic ethers are metabolised by ring-hydroxylation, cleavage of the methyl ether 
(O-demethylation) and/or oxidation of the ring substituents.  
Subgroup 5: Aromatic Ethers Containing a Phenol Ring [FL-no: 04.059, 04.067, 04.068, 04.069, 
04.079, 04.084, 08.127 and 09.687] 
Several studies have demonstrated that anisole [FL-no: 04.032] principally undergoes P450-catalysed 
ring-hydroxylation, preferentially at the p-position, with O-demethylation and o-hydroxylation as the 
minor pathways (Daly and Jerina, 1969; Daly, 1970; Ohi et al., 1992; Takahara et al., 1986).  
Fifteen minutes in vitro incubation of 25 - 50 μmoles of 2-2H-anisole with 3-methylcholanthrene 
(3MC)-induced liver microsomes resulted in o- and p-hydroxylation to form 2- and 4-hydroxyanisole, 
respectively (Daly and Jerina, 1969). In a similar study, 50 μmoles anisole [FL-no: 04.032] incubated 
for 15 minutes with liver homogenates from 3MC-pretreated rats, gave rise to 4 μmoles p-
hydroxyanisole, 0.8 μmoles o-hydroxyanisole and 0.2 μmoles phenol. Thus, in hepatic 3MC induced 
rat microsomes, p-hydroxylation is the major metabolic pathway of anisole biotrasformation, while O-
demethylation and o-hydroxylation are the minor ones (Daly, 1970). In the same study, it is reported 
that ortho-substituents, including methyl groups, greatly reduced the O-demethylation but had little 
effects on para-hydroxylation. The presence of a methyl group in meta position had little effects on 
ortho- and para-hydroxylation of anisole. Para-substitution in the anisole molecule blocked para-
hydroxylation of the ring and markedly stimulate O-demethylation and to a lesser extent meta-
hydroxylation (Daly, 1970). These features are related to 3MC-induced rat microsomes, since in 
hepatic microsomes from control rat and rabbit, para-hydroxylation and O-demethylation are almost 
equally efficient (Daly, 1970).  
The effect of oxygen concentration on the metabolism of anisole [FL-no: 04.032] was investigated in 
a more recent study (Takahara et al., 1986). When phenobarbital-induced rat liver microsomes were 
incubated with 2 mM anisole, in normoxic conditions, comparable levels of phenol (the product of O-
demethylation) and the aromatic hydroxylated products, p-hydroxyanisole and o-hydroxyanisole were 
detected in 10 minutes’ incubations; no m-hydroxylation took place. In hypoxic conditions the levels 
of the 3 metabolites were markedly decreased. When anisole was incubated for 1 hour at different 
oxygen concentrations (24, 34, 54, 74, 113 or 223 μM), the formation rates and the relative amounts 
of metabolites were dependent on the oxygen concentration, as the amount of O-demethylated product 
started decreasing at oxygen concentrations below 60 μM (typical oxygen pressure in the liver was 35 
μM) (Takahara et al., 1986). Results were confirmed in a second study using the same protocol, in 
which also iso-propoxybenzene metabolism was investigated. Although the dependence on pO2 
slightly differs with the two compounds, in both case the main metabolites were due to p-
hydroxylation and O-demethylation with lower formation of the o-hydroxylation product. No m- or 
side chain hydroxylation products were detected (Ohi et al., 1992). 
In vivo experiments on anisole [FL-no: 04.032] confirm that ring-hydroxylation predominates over O-
demethylation. Urine collected 24 hours post-administration of 0.5 g/kg bw of anisole via gavage to 
rabbits revealed that 2 % of the dose was unconjugated p-methoxyphenol (major) and, to a lower 
extent o- methoxyphenol, 48 % was conjugated with glucuronic acid and 29 % was conjugated with 
sulphate. No evidence of ether cleavage was detected (Bray et al., 1953). The limited ether cleavage 
in the rabbit was confirmed by a study with rabbit liver microsomes incubated with 2 μmoles anisole 
for one hour (Axelrod, 1956).  
p-Methylanisole [FL-no: 04.015] administered at 700 mg/rabbit to six rabbits via gavage undergoes 
mainly methyl group oxidation to yield anisic acid (p-methoxybenzoic acid), excreted as the 
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glucuronic acid conjugate in the urine. A smaller amount (27 %) of p-methylanisole is demethylated 
and excreted in the urine as the sulphate or glucuronic acid conjugate of p-cresol. In humans and 
dogs, anisic acid (p-methoxybenzoic acid) is excreted as conjugates of glucuronic acid and glycine 
(Bray et al., 1955). 
The majority of [14C]-p-propylanisole labelled at the methoxy position is metabolised via O-
demethylation, resulting in the expiration of 14CO2, α- and ω-1 oxidation of the side-chain, leading to 
1’- and 2’-hydroxy-p-propylanisole, excreted in the urine and side-chain degradation yielding p-
methoxyhippuric acid found in the urine conjugated with glycine (see Figure III.2). Radiolabeled p-
propylanisole was administered to groups of female Wistar albino rats via oral intubation and to male 
CD-1 mice via the intraperitoneal route at dose levels of 0.05, 0.5, 5, 50, 500 or 1500 mg/kg bw for 
both species. The excretion pathway greatly varied with dose. At the lowest dose level (0.05 mg/kg 
bw/day), the majority of the radioactivity is excreted as 14CO2 in expired air (81.6 and 74.5 % in rats 
and mice, respectively) compared to urinary excretion (8.0 and 15.0 % in rats and mice, respectively) 
within 72 hours. At the low dose levels, the major urinary metabolites were p-methoxyhippuric acid 
and 2’-hydroxy-p-propylanisole. As dose levels increased, a metabolic shift to α- and ω-1 
hydroxylation occurred, yielding greater amounts of the glucuronic acid urinary conjugates of 1’- and 
2’-hydroxy-p-propylanisole and the side-chain degradation product, p-methoxybenzoic acid 
conjugated with glycine. At the highest dose levels (500 or 1500 mg/kg bw) 1’- and 2’-hydroxy-p-
propylanisole were present in the urine also as unconjugated products. Based on this study and other 
available studies in literature on structurally related substances such as trans-anethole (p-
propenylanisole) and estragole, the plausible metabolic routes of p-propylanisole in rats and mice are 
presented in Figure III.2 (Sangster et al., 1983). 
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Figure III.2  Metabolism of p-propylanisole in rats and humans. 
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At low doses, the O-demethylation pathway for the metabolism of p-propylanisole predominates in 
humans as well. In a study in humans, two male volunteers were administered a gelatin capsule 
containing 100 μg [14C]-p-propylanisole (1.5 μg/kg bw). The majority (42.7 %) of the radioactivity 
was accounted for as exhaled 14CO2 within 48 hours, demonstrating that O-demethylation was the 
principal metabolic pathway for p-propylanisole. Comparison with results obtained with anethole and 
estragole, clearly indicates that p-propylanisole, which has a saturated side-chain, is more efficiently 
and extensively O-demethylated than its two unsaturated congeners. The principal metabolic products 
identified in the urine included the glycine conjugate of 4-methyoxybenzoic acid and the glucuronides 
of 1- and 2-hydroxy-p-propylanisoles and 1,2-dihydroxy-p-propylanisoles (Sangster et al., 1987). 
p-Dimethoxybenzene [FL-no: 04.034] administered via gavage at 700 mg/kg bw to rabbits undergoes 
extensive O-demethylation to p-methoxyphenol (34 %) followed by excretion as a glucuronic acid or 
sulphate conjugate. Trace amounts of hydroquinone were reported. O-Demethylation of p-
dimethoxybenzene was also reported to occur in vitro with rabbit liver slices (Bray et al., 1955). 
The candidate aromatic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 
08.127 and 09.687] are expected to be metabolised by ring-hydroxylation (mainly in the para position, 
cleavage of the methyl ether (O-demethylation) and/or oxidation of the ring substituents depending on 
the position of substituents. These products would then be expected to be conjugated primarily with 
glucuronic acid and to a lesser extent sulphate or glycine and excreted in the urine. 2-(4-
Methoxyphenoxy)propionic acid [FL-no: 08.127] is expected to be excreted as such or after 
conjugation. 
No metabolism studies were found for the candidate substance, but data are available on the 
supporting substance 2-methoxynaphthalene 
Subgroup 6: Naphthol Ethers [FL-no: 04.075] 
[FL-no: 04.074]. 2-Methoxynaphthalene is excreted as a 
glucuronic acid conjugate with the methyl ether linkage intact. The exact position of the glucuronic 
acid residue on the naphthyl moiety was not identified (Williams, 1959). 
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether 
[FL-no: 03.024], data are available on substances that are supporting for the metabolism of longer 
chain ethers. Tsuji et al., concluded that dealkylation of ethers becomes less likely as the chain length 
increases and that ω-oxidation is more likely to occur (Tsuji et al., 1978). 
Subgroup 7: Long Chain Aliphatic Ethers [FL-no: 03.024] 
Male IISc rats were given [1-3H] geraniol in daily doses of 800 mg/kg bw by gavage for 20 
consecutive days. Five urinary metabolites were identified via two primary pathways. In one pathway, 
the alcohol is oxidised to yield geranic acid (3,7-dimethyl-2,6-octadienoic acid) which is subsequently 
hydrated to yield 3,7-dimethyl-3-hydroxy-6-octenoic acid (3-hydroxy citronellic acid). In a second 
pathway, the alcohol undergoes selective ω-oxidation of the C8-methyl to yield 8-hydroxygeraniol 
and 8-carboxygeraniol, the latter of which undergoes further oxidation to the principal urinary 
metabolite 2,6-dimethyl-2,6-octadienedioic acid. It was demonstrated that administration of geraniol 
at a dose of 600 mg/kg bw by gavage for 1, 3 or 6 days induced expression of rat liver microsomal 
cytochrome P450 and geraniol hydroxylation, but not the activities of rat liver microsomal 
cytochrome b5, NADPH-cytochrome c reductase, and NADH-cytochrome c reductase, nor the 
activities of these enzymes in rat lung microsomes. Rabbits are also capable of ω-oxidation of 
geraniol, as both the Hildebrandt acid (2,6-dimethyl-2,6-octdienedioic acid and its dihydro form (2,6-
dimethyl-2-octendioic acid; reduced or dihydro-Hildebrandt acid) were isolated from the urine of 
treated animals (Fischer and Bielig, 1940; Asano and Yamakawa, 1950). In both rabbits and rats, the 
ω-hydroxylation is mediated by the cytochrome P450 system and requires NADPH and oxygen. It has 
been demonstrated that not only rat liver microsomes are capable of ω-hydroxylating geraniol, but 
also rat lung and kidney microsomes (JECFA, 2004b). 
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Unlike geraniol, digeranyl ether does not have free hydroxyl groups to facilitate other routes of 
biotransformation, therefore this would increase the likelyhood that ω-oxidation will occur. 
It would be anticipated that following ω-oxidation the resulting metabolites will undergo 
glucuronidation and be excreted in the urine in a similar way to the aliphatic saturated tertiary 
alcohols found in FGE.18, Revision 1 (EFSA, 2009) and the non-polar hydrocarbons found in 
FGE.25Rev2 (EFSA Scientific Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF), 2011). 
III.4. Summary and Conclusions 
The candidate substances are aliphatic, alicyclic or aromatic ethers. On the basis of their structures 
they can be divided into seven subgroups: 1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022], 2) 
alicyclic ethers [FL-no: 03.008,13.170 and 13.200], 3) alicyclic hydrocarbons with an ether side chain 
[FL-no: 02.247, 02.248 and 03.020], 4) benzyl ethers [FL-no: 03.011 and 03.012], 5) phenol ethers 
[FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687], 6) naphthol ethers [FL-
no: 04.075] and 7) long chain aliphatic ethers [FL-no: 03.024]. 
No data on absorption, distribution, metabolism or elimination are reported for the 21 candidate 
substances. 
According to the available data on supporting substances, the aliphatic ethers in subgroup 1 [FL-no: 
03.015, 03.016 and 03.022], the cyclic ethers in subgroup 2 [FL-no: 03.008, 13.170 and 13.200], the 
cyclic hydrocarbon with ether side chain in subgroup 3 [FL-no: 02.247, 02.248 and 03.020], the 
benzyl ethers in subgroup 4 [FL-no: 03.011 and 03.012] and the phenolic ethers in subgroup 5 [FL-no: 
04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687] and the long chain aliphatic ether 
in subgroup 7 [FL-no: 03.024] are all expected to be rapidly absorbed from the gastrointestinal tract 
and excreted in the exhaled air as CO2 and as polar metabolites in the urine.  
After absorption, the supporting substance, beta-naphthyl methyl ether [FL-no: 04.033], 
representative for the ether in subgroup 6, 1-methoxynaphthalene [FL-no: 04.075], is hydroxylated 
and excreted as a glucuronide. 
Concerning their biotransformation, it can be expected that the straight-chain aliphatic ethers included 
in the subgroup 1 may undergo O-dealkylation in vivo, catalysed by P450 to yield the corresponding 
alcohol and aldehyde that subsequently undergo complete oxidation in the fatty acid pathway and 
tricarboxylic acid cycle. The demethylated product of 1-methoxy-1-decene [FL-no: 03.022] is an enol, 
which will rearrange to the aldehyde, which subsequently can be oxidised to the carboxylic acid. 
On the basis of information on representative supporting substances, the candidate alicyclic ethers 2-
acetoxy-1,8-cineole [FL-no: 03.008], 2S-cis-tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H-pyran 
[FL-no: 13.170] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyren [FL-no: 13.200] within 
subgroup 2 may be anticipated to undergo ring-hydroxylation by P450 and conjugation with 
glucuronic acid followed by excretion in the urine. 
The available data suggest that the substance in subgroup 3, alpha-Terpinyl methyl ether [FL no: 
03.020] would be metabolised by P450 isoenzymes to yield polar hydroxylated metabolites, which are 
excreted as glucuronic acid conjugates or further oxidised and then excreted. Cleavage of the ether is 
a minor metabolic pathway (JECFA, 1999a). The JECFA considered the metabolism of alpha-
terpineol at their 51st meeting and they concluded that in humans and animals, terpenoid tertiary 
alcohols are conjugated primarily with glucuronic acid and are excreted in the urine and faeces. 
Unsaturated terpenoid alcohols may undergo allylic oxidation to form polar diol metabolites, which 
may be excreted either free or conjugated. The acetal moiety in vanillin 3-(l-menthoxy)propane-1,2-
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diol acetal [FL-no: 02.248] is shown to be hydrolysed, resulting in the formation of the corresponding 
ether and vanillin. It is expected that the alcoholgroups in this ether subsequently are oxidised and 
that the carboxylic acid(s) are conjugated and then excreted or are excreted as the acid itself. 
Similarly, l-menthoxy ethanol [FL-no: 02.247] is anticipated to be oxidised to the corresponding 
carboxylic acid and excreted. 
The benzyl ethers found in subgroup 4 [FL-no: 03.011 and 03.012] are expected to be metabolised in 
a similar way to mono alkyl derivatives of benzene. It is generally accepted that mono-alkyl 
derivatives of benzene are metabolised by biotransformation of the side chain to produce alcohols and 
carboxylic acids, which are eliminated in the urine as conjugates of glucuronic acid or glycine 
(Williams, 1959).  
The candidate aromatic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 
08.127 and 09.687] are expected to be metabolised by ring-hydroxylation (mainly in the para position, 
cleavage of the methyl ether (O-demethylation) and/or oxidation of the ring substituents depending on 
the position of substituents. These products would then be expected to be conjugated primarily with 
glucuronic acid and to a lesser extent sulphate or glycine and excreted in the urine. 2-(4-
Methoxyphenoxy)propionic acid [FL-no: 08.127] is expected to be excreted as such or after 
conjugation. 
The naphthol ether [FL-no: 04.075] in subgroup 6 is expected to be excreted as a glucuronic acid 
conjugate with the methyl ether linkage intact.  
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether 
[FL-no: 03.024], data are available on substances that are supporting for the metabolism of longer 
chain ethers. Tsuji et al., concluded that dealkylation of ethers becomes less likely as the chain length 
increases and that ω-oxidation is more likely to occur (Tsuji et al., 1978). The JECFA reviewed the 
safety of geraniol in 2004 (JECFA, 2004b) and they concluded that ω-oxidation of geraniol was a 
common metabolic pathway and that this would result in metabolism to innocuous products. EFSA 
agreed with this view in FGE 72 (EFSA Scientific Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF), 2010). As digeranyl ether contains no free hydroxyl group 
like geraniol, other pathways for metabolism of geraniol are not available for digeranyl ether and 
therefore ω-oxidation is more likely to occur. It would be expected that following ω-oxidation, the 
metabolites would be conjugated with glucuronide and excreted in the urine. 
It can be anticipated that the 21 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 
03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 
08.127, 09.687, 13.170 and 13.200] are metabolised to innocuous products. Although saturation of 
some metabolic pathways has been described, it occurs at very high doses, unlikely to be reached by 
the candidate substances when used as flavourings at the estimated levels of intakes. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
AUC  Area Under Curve 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EROD  EthoxyRresorufin-O-Deethylase 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GI   GastroiIntestinal 
GLP  Good Laboratory Practice 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MC  MethylCholanthrene 
MROD  MethoxyResorufin-O-Demethylase 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
MTBE  Methyl Tertiary-Butyl Ether 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
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NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  The Organisation for Economic Co-operation and Development 
PB  PhenoBarbital 
PROD  PentoxyResorufin-O-Depenylase 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
TBA  Tertiary-Butyl Alcohol 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
